{"count":26,"next":"https://lda.gov/api/v1/filings/?filing_specific_lobbying_issues=H.R.+9102&filing_year=2026&ordering=-filing_year&page=2","previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/67b5714f-7362-43a2-86fd-22759280fe17/","filing_uuid":"67b5714f-7362-43a2-86fd-22759280fe17","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/67b5714f-7362-43a2-86fd-22759280fe17/print/","filing_document_content_type":"text/html","income":null,"expenses":"890000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-07-16T16:09:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #480","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S._____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. ___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act HR 5509, Safe Step Act, Provisions related step therapy protocols H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7391, the Community Health Center Drug Pricing Protection Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First S. 891, Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S.4784, An original bill to authorize appropriations for fiscal year 2027 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes, Provisions related to the pharmaceutical industry. Smucker's VICP bill Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Vaccine policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/51d75eff-98f5-4f00-bfd3-c975cd085c89/","filing_uuid":"51d75eff-98f5-4f00-bfd3-c975cd085c89","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/51d75eff-98f5-4f00-bfd3-c975cd085c89/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jonathon Jones, Partner","dt_posted":"2026-07-19T15:50:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127114,"url":"https://lda.gov/api/v1/clients/127114/","client_id":1000493,"name":"ASTRAZENECA","general_description":null,"client_government_entity":false,"client_self_select":null,"state":null,"state_display":null,"country":"","country_display":"* Undetermined","ppb_state":null,"ppb_state_display":null,"ppb_country":"","ppb_country_display":"* Undetermined","effective_date":"2007-07-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the 340B Program - Public Health Service Act (PL 78-410).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107259,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"KIRKLAND","last_name":"TWOMEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"Issues related to the Department of Defense, Uniform Formulary Beneficiary Advisory Panel.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":107259,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"KIRKLAND","last_name":"TWOMEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to H.R. 9102 - Biotech Investment National Security Act of 2026 (BINSA).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107259,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"KIRKLAND","last_name":"TWOMEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/70494441-3fb4-4099-829b-ffd9b717efe3/","filing_uuid":"70494441-3fb4-4099-829b-ffd9b717efe3","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/70494441-3fb4-4099-829b-ffd9b717efe3/print/","filing_document_content_type":"text/html","income":null,"expenses":"140000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Christopher Porter","dt_posted":"2026-07-20T08:09:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3611 Valley Centre Drive","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401104190,"url":"https://lda.gov/api/v1/registrants/401104190/","house_registrant_id":null,"name":"TRAVERE THERAPEUTICS","description":"Pharmaceuticals","address_1":"3611 Valley Centre Drive","address_2":"Suite 300","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER PORTER","contact_telephone":"+1 877-969-7879","dt_updated":"2026-07-20T10:56:00.116563-04:00"},"client":{"id":200929,"url":"https://lda.gov/api/v1/clients/200929/","client_id":12,"name":"TRAVERE THERAPEUTICS","general_description":"Biopharmaceuticals","client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/feccdeab-d3ee-452f-a646-58ccb2b6a903/","filing_uuid":"feccdeab-d3ee-452f-a646-58ccb2b6a903","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/feccdeab-d3ee-452f-a646-58ccb2b6a903/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Stacey Scholl","dt_posted":"2026-07-20T09:08:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 Maine Ave. SW Floor 7","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":75557,"url":"https://lda.gov/api/v1/registrants/75557/","house_registrant_id":36051,"name":"CORNERSTONE GOVERNMENT AFFAIRS, INC.","description":"Government relations and consulting.","address_1":"800 Maine Ave. SW Floor 7","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STACEY SCHOLL","contact_telephone":"+1 202-370-1015","dt_updated":"2026-07-15T15:23:57.752080-04:00"},"client":{"id":56037,"url":"https://lda.gov/api/v1/clients/56037/","client_id":56037,"name":"JOHNS HOPKINS UNIVERSITY","general_description":"Healthcare and medical research","client_government_entity":null,"client_self_select":false,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-04-11"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Monitored Consolidated Appropriations Act, 2026 (H.R. 7148); Monitored Continuing Appropriations and Extensions Act, 2026; Monitored Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; Monitored and advised on FY 2026 and FY 2027 Appropriations research funding; Monitored and advised on research indirect costs Monitored and advised on FY 2026 and FY 2027 Labor, Health and Human Services, and Education Appropriations; Monitored implementation of H.R. 1, One Big Beautiful Bill Act; Monitored Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025; Advised on High-throughput Materials Discovery For Extreme conditions (HTMDEC) funding.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Advised and monitored higher education issues; Monitored and advised on medical school nutrition education; Monitored and advised on military education programs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Monitored Medicaid state directed payments and provider taxes; Monitored implementation of H.R. 1, the One Big Beautiful Bill Act; Monitored Medicare physician reimbursement issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Monitored tax-exempt status for nonprofit organizations; Monitored H.R. 9504, the Tax-exempt Hospital Transparency Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Monitored and advised on Artificial Intelligence; Monitored S.854/H.R. 1864 - Risky Research Review Act; Monitored H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; Monitored and advised on H.R. 9102, the Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Monitored National Defense Authorization Act for FY 2027.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"Monitored H1-B visa fees.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advised on U.S. Family Health Plan; Monitored H.R. 9393, the Lower Costs, More Transparency Act of 2026; Monitored H.R. 9390, the Prices on the Wall Act of 2026; Monitored H.R. 6248/S.4027, the Healthy Competition For Better Care Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/279c4bfe-cffd-4a35-9cae-bfe27a353562/","filing_uuid":"279c4bfe-cffd-4a35-9cae-bfe27a353562","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/279c4bfe-cffd-4a35-9cae-bfe27a353562/print/","filing_document_content_type":"text/html","income":"130000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Adam J. Biegel","dt_posted":"2026-07-20T11:22:25-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"THE ATLANTIC BUILDING","registrant_address_2":"950 F STREET, NW","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":1182,"url":"https://lda.gov/api/v1/registrants/1182/","house_registrant_id":31748,"name":"ALSTON & BIRD LLP","description":"Law Firm","address_1":"THE ATLANTIC BUILDING","address_2":"950 F STREET, NW","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ADAM J. BIEGEL","contact_telephone":"+1 202-239-3692","dt_updated":"2026-07-20T16:02:02.800694-04:00"},"client":{"id":72258,"url":"https://lda.gov/api/v1/clients/72258/","client_id":72258,"name":"CURIE BIO OPERATIONS, LLC","general_description":"Venture Capital Firm and Biotech Accelerator","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-04-01"},"lobbying_activities":[{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/279c4bfe-cffd-4a35-9cae-bfe27a353562/","filing_uuid":"279c4bfe-cffd-4a35-9cae-bfe27a353562","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/279c4bfe-cffd-4a35-9cae-bfe27a353562/print/","filing_document_content_type":"text/html","income":"130000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Adam J. Biegel","dt_posted":"2026-07-20T11:22:25-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"THE ATLANTIC BUILDING","registrant_address_2":"950 F STREET, NW","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":1182,"url":"https://lda.gov/api/v1/registrants/1182/","house_registrant_id":31748,"name":"ALSTON & BIRD LLP","description":"Law Firm","address_1":"THE ATLANTIC BUILDING","address_2":"950 F STREET, NW","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ADAM J. BIEGEL","contact_telephone":"+1 202-239-3692","dt_updated":"2026-07-20T16:02:02.800694-04:00"},"client":{"id":72258,"url":"https://lda.gov/api/v1/clients/72258/","client_id":72258,"name":"CURIE BIO OPERATIONS, LLC","general_description":"Venture Capital Firm and Biotech Accelerator","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-04-01"},"lobbying_activities":[{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/279c4bfe-cffd-4a35-9cae-bfe27a353562/","filing_uuid":"279c4bfe-cffd-4a35-9cae-bfe27a353562","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/279c4bfe-cffd-4a35-9cae-bfe27a353562/print/","filing_document_content_type":"text/html","income":"130000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Adam J. Biegel","dt_posted":"2026-07-20T11:22:25-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"THE ATLANTIC BUILDING","registrant_address_2":"950 F STREET, NW","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":1182,"url":"https://lda.gov/api/v1/registrants/1182/","house_registrant_id":31748,"name":"ALSTON & BIRD LLP","description":"Law Firm","address_1":"THE ATLANTIC BUILDING","address_2":"950 F STREET, NW","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ADAM J. BIEGEL","contact_telephone":"+1 202-239-3692","dt_updated":"2026-07-20T16:02:02.800694-04:00"},"client":{"id":72258,"url":"https://lda.gov/api/v1/clients/72258/","client_id":72258,"name":"CURIE BIO OPERATIONS, LLC","general_description":"Venture Capital Firm and Biotech Accelerator","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-04-01"},"lobbying_activities":[{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/279c4bfe-cffd-4a35-9cae-bfe27a353562/","filing_uuid":"279c4bfe-cffd-4a35-9cae-bfe27a353562","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/279c4bfe-cffd-4a35-9cae-bfe27a353562/print/","filing_document_content_type":"text/html","income":"130000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Adam J. Biegel","dt_posted":"2026-07-20T11:22:25-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"THE ATLANTIC BUILDING","registrant_address_2":"950 F STREET, NW","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":1182,"url":"https://lda.gov/api/v1/registrants/1182/","house_registrant_id":31748,"name":"ALSTON & BIRD LLP","description":"Law Firm","address_1":"THE ATLANTIC BUILDING","address_2":"950 F STREET, NW","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ADAM J. BIEGEL","contact_telephone":"+1 202-239-3692","dt_updated":"2026-07-20T16:02:02.800694-04:00"},"client":{"id":72258,"url":"https://lda.gov/api/v1/clients/72258/","client_id":72258,"name":"CURIE BIO OPERATIONS, LLC","general_description":"Venture Capital Firm and Biotech Accelerator","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-04-01"},"lobbying_activities":[{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152066,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"FRIEDEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71785,"prefix":null,"prefix_display":null,"first_name":"JANE","nickname":null,"middle_name":null,"last_name":"LUCAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148928,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"GRAF","suffix":null,"suffix_display":null},"covered_position":"Deputy Assistant Secretary for Legislation, Department of Health and Human Services; Senate Finance Health Subcommittee Staff Director, Legislative Assistant, Legislative Aide, Deputy Scheduler, Staff Assistant, Senator Debbie Stabenow.","new":true},{"lobbyist":{"id":143067,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"JAGODA","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153630,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"PEZZELLA","suffix":null,"suffix_display":null},"covered_position":"Legislative Intern, Rep. Mike McIntyre; Special Assistant, Senator Claire McCaskill; Legislative Correspondent, Senator Claire McCaskill.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5ad8f848-d4e0-4bdf-b014-99812a46595b/","filing_uuid":"5ad8f848-d4e0-4bdf-b014-99812a46595b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/5ad8f848-d4e0-4bdf-b014-99812a46595b/print/","filing_document_content_type":"text/html","income":null,"expenses":"700000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-07-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5ad8f848-d4e0-4bdf-b014-99812a46595b/","filing_uuid":"5ad8f848-d4e0-4bdf-b014-99812a46595b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/5ad8f848-d4e0-4bdf-b014-99812a46595b/print/","filing_document_content_type":"text/html","income":null,"expenses":"700000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-07-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/dd31025d-92a7-4fb3-87ab-b3fc6ae1d498/","filing_uuid":"dd31025d-92a7-4fb3-87ab-b3fc6ae1d498","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/dd31025d-92a7-4fb3-87ab-b3fc6ae1d498/print/","filing_document_content_type":"text/html","income":null,"expenses":"1880000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Skelton","dt_posted":"2026-07-20T12:39:34-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1275 Pennsylvania Avenue, NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":31326,"url":"https://lda.gov/api/v1/registrants/31326/","house_registrant_id":31354,"name":"PFIZER INC.","description":"Biopharmaceuticals","address_1":"1275 Pennsylvania Avenue, NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-08-21T13:00:31.079287-04:00"},"client":{"id":138225,"url":"https://lda.gov/api/v1/clients/138225/","client_id":12,"name":"PFIZER INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-15"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1 - An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72512,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"CLAEYS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69774,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7f892462-d586-4f79-a9fa-8025deea583d/","filing_uuid":"7f892462-d586-4f79-a9fa-8025deea583d","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7f892462-d586-4f79-a9fa-8025deea583d/print/","filing_document_content_type":"text/html","income":null,"expenses":"240000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Bill McCarthy","dt_posted":"2026-07-20T13:12:53-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1800 M Street, NW, Suite 800 S","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":401105458,"url":"https://lda.gov/api/v1/registrants/401105458/","house_registrant_id":null,"name":"FDD ACTION","description":"Issue advocacy on U.S. national security and foreign policy","address_1":"1800 M Street, NW, Suite 800 S","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MCCARTHY","contact_telephone":"+1 202-207-0190","dt_updated":"2026-07-17T14:19:22.246604-04:00"},"client":{"id":203727,"url":"https://lda.gov/api/v1/clients/203727/","client_id":12,"name":"FDD ACTION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-10-01"},"lobbying_activities":[{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"H.R. 1422, Enhanced Iran Sanctions Act, all provisions. H.R. 1800, Solidify Iran Sanctions Act (SISA), all provisions. H.R. 2683, Remote Access Security Act, all provisions. H.R. 3447, Chip Security Act, all provisions. H.R. 425, Repealing Big Brother Overreach Act, all provisions. H.R. 4397, Muslim Brotherhood Terrorist Designation Act of 2025, all provisions. H.R. 4505, Export Controls Enforcement Act, all provisions. H.R. 4530, STOP Shells Act, all provisions. H.R. 4920, BIS IT Modernization Act, all provisions. H.R. 4930, Counterfeit Notification Act, all provisions. H.R. 5490, Dismantle Foreign Scam Syndicates Act, all provisions. H.R. 5853, ECRA Penalty Increase Act, all provisions. H.R. 6058, Semiconductor Technology Resilience, Integrity, and Defense Enhancement (STRIDE) Act, all provisions. H.R. 6322, Stop Stealing Our Chips Act, all provisions. H.R. 6331, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. H.R. 6624, Biological Intellectual Property Protection Act of 2025, all provisions. H.R. 6875, AI OVERWATCH Act, all provisions. H.R. 6996, Full AI Stack Export Promotion Act, all provisions. H.R. 7003, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. H.R. 7184, Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, all provisions. H.R. 7552, CBW Fentanyl Act, all provisions. H.R. 8036, Interagency Coordination in Export Controls Act, all provisions. H.R. 8106, Rosatom Energy Sanctions Compliance and Unified Enforcement (RESCUE) Act, all provisions. H.R. 8169, Export Control Enforcement and Enhancement Act, all provisions. H.R. 8170, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. H.R. 8202, ECRA Statute of Limitations Extension, all provisions. H.R. 8283, Deterring American AI Model Theft Act of 2026, all provisions. H.R. 8284, Bureau of Industry and Security License Administration Enhancement Act, all provisions. S. 1473, Stop Stealing our Chips Act, all provisions. S. 1490, Global Hunt for Offshore Smuggling and Trafficking (GHOST) Act of 2025, all provisions. S. 1705, Chip Security Act, all provisions. S. 1889, Solidify Iran Sanctions Act (SISA), all provisions. S. 2293, Muslim Brotherhood Terrorist Designation Act of 2025, all provisions. S. 2677, Counterfeit Notification Act, all provisions. S. 2904, Sanctioning Harbors and Dodgers of Western Sanctions (SHADOW) Fleets Act, all provisions. S. 3172, A bill to repeal certain Acts that impose sanctions upon Syria, all provisions. S. 3452, Biological Intellectual Property Protection Act of 2025, all provisions. S. 3519, Remote Access Security Act, all provisions. S. 4281, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. S. 4446, Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, all provisions. S. 4456, AI OVERWATCH Act, all provisions. S. 4723, Eliminate PRC Organized Crime Act, all provisions. S. 4835, Bureau of Industry and Security License Administration Enhancement Act, all provisions. S. 556, Enhanced Iran Sanctions Act of 2025, all provisions. S. 63, CBW Fentanyl Act, all provisions. Issues Related to American Economic Statecraft; Anti-Money Laundering and Combating the Financing of Terrorism; Captagon, Fentanyl, and International Narcotics Production and Trafficking; China-Related Tax and Investment Authorities; Chinese Access to U.S. Capital Markets and Advanced Technology; DIB Capacity Tax Incentives; Evaluating Sanctions, Export Controls, and AML Regulations, Regulatory Authorities, and Legislative Authorities; Expansion of CFIUS Authorities; Foreign Investment in Latin America; Hezbollah, Iran, and IRGC Funding Streams; Implementation and Oversight of the Corporate Transparency Act; Implementation and Oversight of the Countering Americas Adversaries Through Sanctions Act (CAATSA); Implementation and Oversight of the Foreign Extortion Prevention Act; Iranian Oil Sanctions Enforcement; Muslim Brotherhood Funding Streams; National Security-Related Foreign Investment Screening Processes for U.S. Allies; Tax-Exempt Status of Organizations with Ties to U.S. Adversaries; U.S. Adversaries Illicit Finance Activities; U.S. Adversaries Sanctions Evasion Schemes; U.S. Anti-Corruption Sanctions and Strategy; U.S. China Sanctions Policy; U.S. Cuba Sanctions Policy; U.S. Export Control Policy; U.S. Houthi Sanctions Policy; U.S. International Sovereign Debt Policy; U.S. Investment Screening and Security; U.S. Iran Sanctions Policy; U.S. Iraq Sanctions Policy; U.S. Muslim Brotherhood Sanctions Policy; U.S. Nicaragua Sanctions Policy; U.S. Oman Sanctions; U.S. Polisario Front Sanctions Policy; U.S. Russia Oil Waivers and Sanctions Policy; U.S. Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; U.S. Syria Sanctions Policy; U.S. Terror Finance Policy; and U.S. Turkey Sanctions Policy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145330,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":"NICK","middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"H.Con.Res. 38, Directing the President pursuant to section 5(c) of the War Powers Resolution to remove United States Armed Forces from unauthorized hostilities in the Islamic Republic of Iran, all provisions. H.Con.Res. 40, Directing the President, pursuant to section 5(c) of the War Powers Resolution, to remove United States Armed Forces from hostilities with Iran, all provisions. H.Con.Res. 75, Directing the President, pursuant to section 5(c) of the War Powers Resolution, to remove the United States Armed Forces from hostilities against the Islamic Republic of Iran, all provisions. H.Con.Res. 84, Directing the President pursuant to section 5(c) of the War Powers Resolution to remove United States Armed Forces from Lebanon, all provisions. H.Con.Res. 86, Directing the President, pursuant to section 5(c) of the War Powers Resolution, to remove United States Armed Forces from hostilities with Iran, all provisions. H.J.Res. 176, 2026 Authorization for Use of Military Force Against Iran, all provisions. H.J.Res. 200, Providing for congressional disapproval of the proposed foreign military sale to Turkey of certain defense articles and services, all provisions. H.R. 2505, Block the Use of Transatlantic Technology in Iranian Made Drones Act, all provisions. H.R. 7126, Securing Essential and Critical U.S. Resources and Elements (SECURE) Minerals Act, all provisions. H.R. 7146, Providing Our Regional Companions Upgraded Protection in Nefarious Environments (PORCUPINE) Act, all provisions. H.R. 7178, U.S.-Israel Anti-Killer Drone Act, all provisions. H.R. 7273, NASA Reauthorization Act of 2026, all provisions. H.R. 7540, United States-Israel Framework for Upgraded Technologies, Unified Research, and Enhanced Security (FUTURES) Act of 2026, all provisions. H.R. 8019, U.S.-Greece Defense Cooperation Advancement Act, all provisions. H.R. 8069, Strategic Subsea Cables Act of 2026, all provisions. H.R. 8168, Major Non-NATO Ally Terror Threat Assessment Act, all provisions. H.R. 8177, Critical Undersea Infrastructure Resilience Initiative Act, all provisions. H.R. 8649, Expanding the Defense Industrial Base Sales Act, all provisions. H.R. 8665, Allied Defense Sales Act, all provisions. H.R. 8787, Servicemember Payment Data Privacy and Security Act, all provisions. H.R. 9232, Critical Infrastructure Airspace Defense Act, all provisions. H.R. 9256, Ending Child Soldiers in Africa Act, all provisions. H.R. 9322, Abraham Accords Defense Cooperation Act of 2026, all provisions. H.R. 9366, Eastern Frontier Defense Infrastructure Readiness Act, all provisions. H.R. 9451, Seized Assets for Battlefield Equipment and Readiness (SABER) Act, all provisions. H.R. 9495, Department of Defense Appropriations Act, 2027, (issues related to U.S.-Ukraine Security Cooperation). H.R. 9550, Strategic Unmanned Systems Partnership Act, all provisions. H.Res. 1246, Expressing the sense of the House of Representatives in support of the integration of Kosovo into the North Atlantic Treaty Organization, all provisions. H.Res. 564, Calling for the return of abducted Ukrainian children before finalizing any peace agreement to end the war against Ukraine, all provisions. S. 1744, Providing Our Regional Companions Upgraded Protection in Nefarious Environments (PORCUPINE) Act, all provisions. S. 1962, Secure Space Act of 2025, all provisions. S. 2222, Critical Undersea Infrastructure Resilience Initiative Act, all provisions. S. 3249, Strategic Subsea Cables Act of 2026, all provisions. S. 3404, Satellite Cybersecurity Act of 2025, all provisions. S. 3659, Securing Essential and Critical U.S. Resources and Elements (SECURE) Minerals Act, all provisions. S. 3855, United States-Israel Framework for Upgraded Technologies, Unified Research, and Enhanced Security (FUTURES) Act, all provisions. S. 4219, Abraham Accords Defense Cooperation Act of 2026, all provisions. S. 4380, Critical Infrastructure Airspace Defense Act, all provisions. S. 4443, Eastern Mediterranean Gateway Act, all provisions. S. 4544, Stop Fueling Cartel Violence Act, all provisions. S. 4711, Strategic Unmanned Systems Partnership Act, all provisions. S. 4826, Seized Assets for Battlefield Equipment and Readiness (SABER) Act, all provisions. S. 933, NASA Transition Authorization Act of 2025, all provisions. S.J.Res. 114, A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress, all provisions. S.J.Res. 123, A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress, all provisions. S.J.Res. 163, A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress, all provisions. S.J.Res. 184, A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress, all provisions. S.J.Res. 185, A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress, all provisions. S.Res. 236, A resolution calling for the return of abducted Ukrainian children before finalizing any peace agreement to end the war against Ukraine, all provisions. H.R. 8800, National Defense Authorization Act for Fiscal Year 2027, (issues related to Actions to Evaluate and Invest in Ukrainian Defense Technologies; Additional Support for NATO Air Defense Against UAS; AI Agent Discovery and Security Standards; Air Force Fighter Fleet Recapitalization; Amendment to the Atomic Energy Act of 1954; Amendments to the Anti-Boycott Act of 2018; American Security Robotics Act; American-Hellenic-Israeli Eastern Mediterranean Counterterrorism and Maritime Security Partnership Act; Analysis of Threats Posed by Foreign Adversary Access to Controlled Items Within the US; ARMOR Act; Assessment and Report of Foreign Adversary Influence over Strategic Maritime Chokepoints; Assessment of Antisemitism in the Service Academies; Assessment of DOD Display Chain Supply Chain Vulnerabilities; Assessment of Foreign Adversary-Controlled Digital Platforms; Assessment of Military Medical Supply Chains; Assessment of Resilient Missile Defense Sensing Architectures; Assessment of Russian Involvement in Narcotics and Narcotics Trafficking; Audit and Mitigation of Certain Cellular Modules; Audit of CCP-Linked Participation in DOD Contracts and Supply Chains; Baltic Region Security Concerns; Biological Intellectual Property Protection Act; Biotech Investment National Security Act; Briefing on Supply Chain Exposure; Briefing on the Pilot Program to Analyze and Monitor Certain Supply Chains; Bunker Buster Act; Certification Requirement for Motor Carriers Transporting DOD Freight; Certification That No Contractor of DOD Participates in BDS Movement; Chinese Cellular Modules; Chinese Commercial Space Capabilities; Chinese Robotics Capabilities and Strategy; Chinese Supply Chain Monopoly Identification and Diversification; Civilian Cybersecurity Reserve Corps Pilot Program; Clarification of Authority to Counter UAS for Members of the National Guard; Classification of Pass-Through Funding Within Defense Budget Materials; CLEAR Path Act; Codification of EOs Relating to American Airspace Sovereignty and Drone Dominance; Commercial Software for Contested Logistics; Countering Adversarial Gray Zone Campaigns; Countering Biotechnology Threats from Foreign Adversaries; Countering Cartel Hydrocarbon Smuggling; Countering Iranian Threat Networks in the Eastern Mediterranean; Criminal Penalties for Providing Material Support to a Covered Foreign Country; Critical Minerals Traceability Pilot Program; Cyber Incident Reporting Requirements for Operationally Critical Contractors; Deter PRC Aggression Against Taiwan Act; Determination on Eligibility for Cyber Pilot Program; DETERRENCE Act; DETERRENT Act; Development, Test, Evaluation, Demonstration, and Transition to Production of Alternative Low-Cost Weapon Systems; Dialogue and Measures with Respect to Moldova; DIB and Acquisition Reform; Disclosure of Foreign Funding for Elementary and Secondary Schools; DOD Economic Defense Unit; DOD Grant Program to Improve Cybersecurity Resilience of Department-Owned Joint-Use Airports; Domestic and Covered Allied or Partner Country Critical Transportation Manufacturing Assessment; Domestic Production of Short-Wave Infrared Quantum Dot Materials; Electromagnetic Spectrum Operations Review; Elimination of Use of Certain Payment Processing Equipment, Systems, or Services; End the Cyprus Embargo Act; Ensuring Mature-node Semiconductor Availability; Establishment of Army Information Operations Center of Excellence; Establishment of China Watcher Program; Establishment of DIU Office in Israel; Establishment of Eastern Flank NATO Regional SOC and CSIRT Program; Establishment of Strategic Airports Cybersecurity Infrastructure Program; Establishment of US-Israel AI Center; Establishment of US-Ukraine Critical Minerals Investment Screening Mechanism; Evaluation of Standards for EMP Protection; Exceptions for Notifications to the US Government Relating to Specified Foreign Entities; Expanding the Defense Industrial Base Sales Act; Expansion of Permissible Uses of Ukraine Support Fund; Extension and Modification of Indo-Pacific Maritime Security Initiative; Extension and Modification of Report on Military and Security Developments Involving the PRC; Extension of Limitation on Availability of Funds for the Iraqi Security Forces; Extension of Report on IRGC-Affiliated Operatives Abroad; FASC Exclusion Orders for Chinese Military Company Designees; Feasibility of Permanent Basing an F-35 Squadron in Poland; Feasibility Study on Combatant Command Critical Minerals Management; Feasibility Study on Tactical Information Operations Command Authority; GAO Report on AI Integration Across Defense Operations; Government-Wide Critical Mineral Procurement and Resale Authorities Feasibility Study; GPS Modernization; GUARD Act; Guard the Skies Act; Hardware and Firmware Assurance Pilot Program; IMF Reform; Increased Maximum Production Capacity Plans for Key Munitions and Weapons Systems; Indo-Pacific Trilateral Production Pilot Program; Integrated Air and Missile Defense Architecture; Integration of Demand for FMS into Industrial Base Planning; Internal Base Hardening Assessments and Logistics-Node Threat Mitigation; Joint DOD-DHS Security Pilot Program on Prevention of Terrorist Threats Involving Motor Vehicles; Joint US-Taiwan Research, Development, Test, and Evaluation Program; Limitation on Provision of Funds to Elementary and Secondary Schools Hosting Confucius Institutes and Classrooms; Long Range Anti-Ship Missile Surface and Ground Launch; Maritime Security Measures; Medical Supply Chain Risk Identification and Transparency Enhancement; Military Treatment Facility Readiness, Network Reliance, and Cyber Resilience; Modification of Report on Military and Security Developments Involving Russia; Modification of Report on the Military Power of Iran; Modification to Disclosure Requirements for US-Based Foreign Media Outlets; Modifications to Congressional Review of Sanctions with Respect to Russia; Modifications to Public Reporting of Chinese Military Companies Operating in the US; Modifications to Strategy to Eliminate Sourcing of Computer Displays from Certain Nations; Modifications to the Port Security Grant Program; Moldovas Airspace Awareness and Defense Capabilities; MTS Cyber Act; Multiyear Procurement Authorities; National Security Commission on Robotics; NSA Support for DIB and Critical Infrastructure Cybersecurity Operations; Oversight of Military-to-Military Exchanges and Contacts Between the US and Russia; PAID OFF Act; Participation of Ukrainian Students in US Service Academies; Phased Inventory Benchmarks for Combat Coded Fighter Aircraft; Photovoltaic Modules from Foreign Entities of Concern; PILLAR Act; Pilot Program for Adaptive Electronic Warfare-Resilient and Quantum-Secure Autonomy Small UAS Architecture Testing; Pilot Program on DOD Partnerships with IHE Recognized in the NCAE-C Program for Cyber Research; Pilot Program on National Security Risk Identification and Review for Adversarial Capital; Pilot Program on Semiconductor Antitampering and Authenticity Validation; Pilot Program to Improve Participation by Small Business Concerns in Certain DOD Contracts; Plan on Remediation of Certain Equipment and Computational Facilities Owned or Controlled by a Foreign Adversary; Plan Required for Full Participation by Taiwan in the RIMPAC; Plan to Counter PRC Influence and Activities in the FAS; Potential Designation of Information as a Domain of Warfare; PRC Militarization and Surveillance Activities; Procurement of Amoxicillin; Prohibition Against US Recognition of Russia's Claim of Sovereignty over Any Portion of Ukraine; Prohibition on DOD Procurement from, and Servicemember Data Collection by, Companies Storing Data in a Covered Foreign Country; Prohibition on Operation or Procurement of Foreign-Made UAS; Prohibition on Procurement and Operation of Covered Robotic Systems; Prohibition on Procurement by DOD and IC of Chinese-Made Synthetic Datasets for Training AI Models; Prohibition on Transfers to the Badr Organization; Prohibition on TSP Investments; Prohibition on Use of Funds for Ukraine Security Assistance; Protecting US Farmland and Sensitive Sites from Foreign Adversaries Act; Protection of Supply Chain of Certain Drugs; Rail Infrastructure Cybersecurity Enhancement Program; Real-Time and AI-Enabled Property Records; Report and Conditions on Security Assistance to Oman; Report on Accelerating Military Posture Within Area of Responsibility of US INDOPACOM; Report on Counterintelligence Risks Associated with Real Property Transactions Near Military Installations; Report on Dependency on China for Processing Materials for DOD Supply Chains; Report on Forced Conscription of Kidnapped Ukrainian Children into Russian Armed Forces; Report on Foreign-Linked Funding of Legal and Administrative Actions Targeting US and Allied Personnel; Report on Global Automobile Theft Rings; Report on Instances of Antisemitism; Report on Involvement of Certain Foreign Actors in Antisemitic Activity in the US; Report on Military Power and Illicit Activities of Certain Drug Cartels; Report on Modernization of the Aegis Ashore Missile Defense Site at Devesselu, Romania; Report on Moldova Airspace Defense Requirements and Options; Report on PRC Space Capabilities; Report on Production of 155MM Artillery Ammunition; Report on Protection of US Defense Technology; Report on Russias Targeting of Religious Infrastructure in Ukraine; Report on Russian Active Measures in NATO Territory; Report on Russian Efforts in Sudan; Report on Russian Influence in Libya; Report on Russian Influence; Report on Russian Military Presence in Syria; Report on Security Risks Posed by Turkeys Occupation of Cyprus; Report on Taiwan Capabilities and Intelligence Support; Report on the Feasibility of Requiring Bills of Materials for Defense Acquisition; Report on the National Security Implications of Applying Nondiscriminatory Treatment to the PRC; Report on the PRC and Turkey Military and Intelligence Cooperation; Report on Turkey Aiding Hamas or Its Affiliates; Report to Congress on Energy in Moldova; Reporting on Russias Military Power and Capabilities; Reports on Cyber Operational Readiness Assessment Program; Re-Purposing Aircraft from the 309th AMARG; Requirement for Guidance and Prohibition on Use of AI of Certain AI Companies; Requirement for Memoranda of Agreement Regarding Vulnerability Disclosure and Prohibition on Procurement from IT Providers Who Can Share Cyber Vulnerabilities with Countries of Concern; Requirements Related to Certain Sanctions on Russia or Belarus; Restriction on Providing Federal Funds to Certain Entities for Public Works Projects; Restrictions on US Support for Economic Activities Involving Persons Who Benefitted from or Supported the Assad Regime; Review of Intelligence Vulnerabilities of Internet Connected Video Surveillance Equipment on Military Installations; Revocation of Security Clearances for Certain Persons; Safeguarding DOD-Funded Research; Securing Critical US Infrastructure and Mineral Supply Chains; Securing DOD Supply Chains; Securing Innovation and Research from Adversaries Act; Seizure and Forfeiture of Assets of Russian Kleptocrats; Semiconductor Controls Adjusted to Limit Exports Act; Semiconductor Supply Chain Security and Diversification Act; Sense of Congress on Commitment to the AUKUS Partnership; Sense of Congress on Domestic Production of Artillery Projectiles; Sense of Congress on International Defense Exhibitions; Sense of Congress on Nuclear Cooperation Agreements with Saudi Arabia; Sense of Congress on the Gaza Health Ministry; Sense of Congress on the Permanent and Rotational Presence of US Forces in Romania; Sense of Congress Regarding Kosovo Integration into NATO; Sense of Congress Regarding NATO's Kosovo Force; Sense of Congress with Respect to Execution of Warrants of the ICC; Space-Based Missile Defense Strategy; Standards for AI Systems; Strategic Partnership on Defense Industrial Priorities Between the US and Taiwan; Strategy for Establishing a Two-Way Transfer Mechanism for US-Ukraine UAS Expertise; Strategy for the Adoption and Integration of AI; Strategy to Defend Against Risks Posed by the Use of AI; Strategy to Restore Stability to the Western Balkans; Strengthening Continuity of the Economy Planning; Study and Report on International Security Measures on the Border Between Gaza and Egypt; Study, Strategy, and Report on DOD Reliance on Transportation Systems Incorporating Chinese-Origin Components; Taiwan-Five Eyes Cyber Defense Cooperation Initiative; Training for Ukraines Military and National Security Forces; Transatlantic Growth Enterprise Act; Tren de Aragua Border Security Threat Assessment Act; Ukraine Drone Production and Strategy; Ukrainian Military Instructors at Senior Professional Military Education Institutions; Updated Middle East IAMD Strategy; Updates to Certain Asset Lists of the DOD; Upholding the Dayton Peace Agreement Through Sanctions Act; US Counter-Robotics Strategy; US Cybersecurity Capabilities and Strategy; US Drone and Missile Defense Capabilities; US Force Posture in Korea and Europe, US Information Operations Capabilities and Strategy; US International Legal Operations Strategy; US Military Posture in Europe; US-Abraham Accords Defense Cooperation Initiative; US-Cyprus Security Cooperation; USDT Report on Financial Institutions That Support Terrorist Activity; US-European Nuclear Energy Cooperation Act; US-Greece Security Cooperation Reporting Act; US-Israel Cooperation on Space Matters; US-Israel Cooperative Research and Development; US-Israel Defense Technology Cooperation Initiative; US-Israel Security Cooperation; US-Taiwan Security Cooperation; US-Ukraine Drone Working Groups; US-Ukraine EOD Partnership; US-Ukraine Military Trauma Education, Training, Research, and Medical Readiness Partnership; and US-Ukraine Security Cooperation). S. 4784, National Defense Authorization Act for Fiscal Year 2027, (issues related toAbraham Accords Defense Cooperation Initiative; AI Functional Bill of Materials; Analysis of Threats Posed by Foreign Adversary Access to Controlled Items Within the US; Assessment of Taiwans LNG Supply Chains; Assistance to LAF for Countering Hezbollah and Other Terrorist Groups; Audit and Mitigation of Covered Cellular Modules in the DOD Systems and Infrastructure; Briefing on Military and Intelligence Presence of Cuba in the Western Hemisphere; Chinese Cellular Modules; Codification of DOD Research Security Program; Countering Cartel Hydrocarbon Smuggling; Cybersecurity Training for Veterans and Military Spouses; Derived Sourcing Requirements for AI Outputs; DETERRENCE Act; DETERRENT Act; DLA Warstopper Program; DOD Economic Defense Unit; Expansion of Permissible Uses of Ukraine Support Fund; Extension and Modification of Pacific Deterrence Initiative; Extension of Report on Military Power of the PRC; Extension, Modification, and Redesignation of Taiwan Security Cooperation Initiative; Full Accountability for Chinese Military Companies; Inspector General for Foreign Assistance; Internal Base Hardening and Staged Internal Operations; Middle East IAMD Architecture; Modifications to Requirement for Public Reporting of Chinese Military Companies Operating in the US; Multiyear Procurement Authorities; PAID OFF Act; Plan on Remediation of Certain Equipment and Computational Facilities Owned or Controlled by a Foreign Adversary; PRC EMP Capabilities; Report on the Feasibility and Advisability of Establishing a Strategic Partnership on Defense Industrial Priorities between the US and Israel; Reports on Foreign Boycotts of Israel; REVOKE Act; Safeguarding DOD-Funded Research; SECURE Minerals Act; Securing Critical Weapons Systems Supply Chains; Securing US Military Mobility Infrastructure; Securing US Transportation Systems; Stop Foreign Spyware Act; Strategic Subsea Cables Act; Taiwan Energy Security and Embargo Act; Ukraine Drone Production and Strategy; US AI Policy; US Airport Cybersecurity Enhancements; US Critical Infrastructure Resilience Against EMP Weapons; US Cybersecurity Capabilities and Strategy; US Drone and Missile Defense Capabilities; US Healthcare Cybersecurity Enhancements; US Highways Cybersecurity Enhancements; US Indo-Pacific Policy and Strategy; US Maritime Cybersecurity Enhancements; US Rail Infrastructure Cybersecurity Enhancements; US Space Capabilities and Strategy; US-India Security Cooperation; US-Israel Defense Technology Cooperation Initiative; US-Israel Security Cooperation; US-Taiwan Security Cooperation; US-Ukraine Security Cooperation; and US-Ukraine Strategic Defense Innovation Working Group). Issues Related to Air Force Fighter Fleet Recapitalization; Chinas Military-Industrial Complex (CMIC); China-Iran-Russia Security Cooperation and Technology Development; Chinese Military Companies; Counter-Drone Technology Exchanges; Department of Defense Education Policy; Hardening U.S. Military Assets and Bases; Houthi Interdiction Efforts; Implementation and Oversight of the NDAA (FY23 - FY26); Irans Military Strategy and Capabilities; Irans Network of Terror Proxies; Iranian Weapons Proliferation; Operation Epic Fury; PRC Militarization and Surveillance Activities; Preserving Peace and Security in the Eastern Mediterranean; Russias Foreign Policy and Military Strategy; Safeguarding DOD-Funded Research; Securing DOD Supply Chains; U.S. Arms Sales and Procurement Strategies; U.S. CENTCOM Capabilities and Strategy; U.S. Counter-Robotics Strategy; U.S. Critical Mineral Policy and Diplomacy; U.S. DOD Post-Quantum Cryptography; U.S. Drone and Missile Defense Capabilities; U.S. F-35 Program; U.S. Indo-Pacific Strategy and Relations; U.S. Information Operations Capabilities and Strategy; U.S. International Legal Operations Strategy; U.S. Maritime Manufacturing Capacity; U.S. Military Posture in Europe; U.S. Military Posture in the Middle East; U.S. Nigeria Security Cooperation; U.S. Nuclear Deterrence Policy; U.S. Policy on Irans Ballistic Missile and Nuclear Programs; U.S. Policy on Irans Support for Terrorism; U.S. Policy on Russias War in Ukraine; U.S.-Iraq Security Cooperation; U.S.-Israel Security Cooperation; U.S.-Lebanon Security Cooperation; U.S.-NATO Security Cooperation; U.S.-Taiwan Security Cooperation; U.S.-Turkey Security Cooperation; U.S.-Ukraine Security Cooperation; and Ukraine Drone Production and Strategy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145330,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":"NICK","middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"H.R. 2658, Free Iraq from Iran Act, all provisions. H.R. 3307, Eastern Mediterranean Gateway Act, all provisions. H.R. 3563, Taiwan PLUS Act, all provisions. H.R. 36, MEGOBARI Act, all provisions. H.R. 4531, BANNED in Latin America Act, all provisions. H.R. 6230, Tehran Incitement to Violence Act, all provisions. H.R. 6469, Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act, all provisions. H.R. 7380, Internet Reach and Access Now (IRAN) Act, all provisions. H.R. 7567, Farm, Food, and National Security Act of 2026 (issues related to Binational Agricultural Research and Development; CFIUS Consideration of Certain Agricultural Land Transactions; and Rural Water and Wastewater Circuit Rider Program). H.R. 7622, Iran Human Rights, Internet Freedom, and Accountability Act of 2026, all provisions. H.R. 7668, Countering Chinas Control of the Caucasus Act, all provisions. H.R. 8433, Countering Russias War on Faith Act, all provisions. H.R. 8595, National Security, Department of State, and Related Programs Appropriations Act, 2027, (issues related to International Narcotics and Law Enforcement; Democracy Programs in Latin America; and Assistance to South Africa). H.R. 8693, Deter PRC Aggression Against Taiwan Act, all provisions. H.R. 8700, Protecting U.S. Farmland and Sensitive Sites from Foreign Adversaries Act, all provisions. H.R. 8718, Countering Russias Forced Recruitment and Kidnapping in Africa Act, all provisions. H.R. 9020, No U.S. Funding for UNIFIL Act, all provisions. H.R. 9087, To direct the Secretary of State to take actions with respect to certain foreign affairs matters, (issues related to Baltic Regional Security; Gaza Health Ministry; Certification Requirement for Major Arms Sales to Turkey; IGO Anti-Boycott Act; and BANNED in Latin America Act). H.R. 9147, Abraham Accords Expansion Act of 2026, all provisions. H.R. 9450, Countering Russian Trafficking Act, all provisions. H.Res. 1379, Condemning Lebanese Hezbollahs repeated violations of ceasefire agreements and calling for the Lebanese Government to ensure Lebanese Hezbollah immediately ceases all attacks and disarms, in accordance with the ceasefire, all provisions. S. 1824, Taiwan PLUS Act, all provisions. S. 3360, Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act, all provisions. S. 3496, United States Legal Gold and Mining Partnership Act, all provisions. S. 3900, Iran Human Rights, Internet Freedom, and Accountability Act of 2026, all provisions. S. 4192, Property Location Oversight and Transparency (PLOT) Act of 2026, all provisions. S. 4296, IGO Anti-Boycott Act, all provisions. S. 4379, Countering Russias War on Faith Act, all provisions. S. 4392, Energy Security Pacts Act, all provisions. S. 4600, South China Sea Strategy Act of 2026, all provisions. S. 4665, BANNED in Latin America Act, all provisions. S. 4853, United States-Israel Agriculture Cooperation Improvement and Expansion Act, all provisions. H.R. 8800, National Defense Authorization Act for Fiscal Year 2027, (issues related to Abraham Accords Central Asia Expansion Act; Abaraham Accords Authorities Expansion; Accountability for Terrorist Perpetrators of October 7th Act; Arms Delivery Queue Report; Arms Sales and Weapons System Transfers to NATO countries; Authorization of Activities to Counter Russia; BANNED in Latin America Act; Business in the Balkans; Captagon, Fentanyl, and International Narcotics Production and Trafficking; Certification Requirement for Major Arms Sales to Turkey; Closing Loopholes in Russia Sanctions; Countering Russias War on Faith Act; Deployment of a Financial Attache to the US Embassy in Jerusalem; Deterring Adversary Ill-Gotten Gains Act; AI OVERWATCH Act; American Space Leadership for the 21st Century Act; BIS License Administration Enhancement Act; BIS STRENGTH Act; Block the Use of Transatlantic Technology in Iranian Made Drones Act; China AI Power Report Act; Chip Security Act; Countering Chinas Control of the Caucasus; Countering Russias Forced Recruitment and Kidnapping in Africa Act; Deterring American AI Model Theft Act; Dismantle Foreign Scam Syndicates Act; Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act; Decreasing Russia Oil Profits (DROP) Act; ECRA Penalty Increase Act; ECRA Statute of Limitations Extension; Enhanced Iran Sanctions Act; Export Control Enforcement and Enhancement Act; Export Controls Enforcement Act; Foreign Adversary AI Risk Assessment and Diplomacy Act; Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act; Full AI Stack Export Promotion Act; Interagency Coordination in Export Controls Act; Interagency Strategy to Disrupt and Dismantle Narcotics Production and Trafficking and Affiliated Networks Linked to the Regime of Bashar al-Assad in Syria; ITAR Licensing Reform Act; Kleptocracy Asset Recovery Rewards Program Act; Limitation on Contributions to the UN; Limitation on Transfer of Weapons to Turkey; Limitation Regarding Certain Export Controls; Multilateral Alignment of Technology Controls on Hardware (MATCH) Act; MEGOBARI Act; No US Funding for UNIFIL Act; No Official Palestine Entry (NOPE) Act; Participation of Russia in the G7; Preventing the Escalation of Armed Conflict in Europe (PEACE) Act; Peace Through Strength Act; Polisario Front Terrorist Designation Act; Preventing Rogue Equipment for Synthetic Substances (PRESS) Act; Prohibition on Delay of Arms Sales to Taiwan; Remote Access Security Act; REPO Implementation Act; Report on Allied Information Sharing to Counter Foreign Malign Influence; Report on Backlog of FMS to Taiwan; Russia-North Korea Cooperation Sanctions Act; Sanctions List Harmonization Act; Strategic Hybrid Activities Defense and Operations for the West (SHADOW) Act; STOP HATE Act; Stop Stealing Our Chips Act; Strategic Dialogue to Return Democratic Rule to Belarus; Strategic Subsea Cables Act; Streamlining Foreign Military Sales Act; Semiconductor Technology Resilience, Integrity, and Defense Enhancement (STRIDE) Act; Taiwan Allies Fund Act; Taiwan Energy Security and Anti-Embargo Act; Taiwan PLUS Act; US Arms Sales and Procurement Strategies; US Iran Sanctions Policy; US Support for the Iranian People; War Reserve Stockpiles for Allies; and XPCC Sanctions Act). S. 4784, National Defense Authorization Act for Fiscal Year 2027, (issues related to BANNED in Latin America Act; BIS License Administration Enhancement Act; BIS STRENGTH Act; China AI Power Report Act; Chip Security Act; Countering Chinas Control of the Caucuses Act; Critical Undersea Infrastructure Resilience Initiative Act; Deterring American AI Model Theft Act; Eastern Mediterranean Gateway Act; ECRA Statute of Limitations Extension Act; Eliminate PRC Organized Crime Act; FREEDOM Act; Imposition of Sanctions with Respect to Trade in Russian Origin Petroleum Products; Iran Human Rights, Internet Freedom, and Accountability Act; MATCH Act; MEGOBARI Act; No Hezbollah In Our Hemisphere Act; PORCUPINE Act; Religious Infrastructure in Ukraine; Remote Access Security Act; REPO Implementation Act; Sense of Congress on Illegal Abduction of Ukrainian Children by Russia; SHADOW Fleet Sanctions Act; Statement of Policy on Repeal of Sunset of Iran Sanctions Act of 1996; US Iran Sanctions Policy; US Legal Gold and Mining Partnership Act; US Russia Oil Waivers and Sanctions Policy; US Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; US South Africa Bilateral Relations Review Act; and War Reserve Stockpiles for Allies). Issues related to Abraham Accords Authorities; AGOA Reauthorization; Chinas Foreign Policy and Military Strategy; Chinese and Russian Activities in Africa; Chinese Investments in the Middle East; Chinese, Iranian, and Russian Activities in Latin America; Congressional Oversight of U.S. Arms Sales; Congressional Oversight of U.S. Foreign Assistance; Implementation and Oversight of Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026; Implementation and Oversight of Consolidated Appropriations Act, 2026; Implementation and Oversight of Continuing Appropriations, Agriculture, Legislative Branch, Military Construction, and Veterans Affairs, and Extension Act, 2026; Implementation and Oversight of the Iran Nuclear Agreement Review Act; Implementation and Oversight of the National Security Act of 2024; Israel-Syria Relations; Normalization in the Middle East; Protecting International Religious Freedom; Qatars, South Africas, and Turkeys Support of Terrorism; Russias Mass Abduction of Ukrainian Children; Strengthening the National Endowment for Democracy; Support for U.S. Allies at International Organizations; Syria-Turkey Relations; U.S. Contributions to and Oversight of International Organizations; U.S. Energy Security Policy; U.S. Foreign Affairs-Related Appropriations; U.S. Foreign Aid Policy and Reform; U.S. International Development Finance Corporation; U.S. Policy on Chinas Human Rights Abuses and Repression; U.S. Policy on Irans Human Rights Abuses and Censorship; U.S. Support for the Iranian People; U.S. Victims of Terrorism; U.S. Western Balkans Strategy; U.S.-Cuba Policy and Relations; U.S.-Honduras Policy and Relations; U.S.-Iran MOU and Negotiations; U.S.-Iraq Relations; U.S.-Latin America Foreign Policy and Strategy; U.S.-Mexico Policy and Relations; U.S.-Nicaragua Policy and Relations; U.S.-Qatar Policy and Relations; U.S.-South Africa Policy and Relations; U.S.-South Korea Policy and Relations; U.S.-Turkey Policy and Relations; U.S.-Venezuela Energy Policy; U.S.-Venezuela Policy and Relations (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145330,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":"NICK","middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"H.R. 1736, Generative AI Terrorism Risk Assessment Act, all provisions. H.R. 2158, Countering Transnational Repression Act of 2025, all provisions. H.R. 2212, DHS Intelligence Rotational Assignment Program and Law Enforcement Support Act, all provisions. H.R. 3463, Comprehensive Operations for Unmanned-System Neutralization and Threat Elimination Response (COUNTER) Act, all provisions. H.R. 6105, Restricting Ex-Vetted Officials from Knowledge Exploitation (REVOKE) Act, all provisions. H.R. 6106, Conflict-free Leaving Employment and Activity Restrictions (CLEAR) Path Act, all provisions. H.R. 6107, Preventing Adversary Influence, Disinformation, and Obscured Foreign Financing (PAID OFF) Act of 2025, all provisions. H.R. 8022, DETECT Nitazenes Act of 2026, all provisions. H.R. 881, DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act, all provisions. S. 2132, CLEAR Path Act, all provisions. S. 3050, Preventing Adversary Influence, Disinformation, and Obscured Foreign Financing (PAID OFF) Act of 2025, all provisions. S. 3181, REVOKE Act, all provisions. Issues related to Foreign Threats to U.S. Homeland (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"H.R. 4142, No Adversarial AI Act, all provisions. H.R. 6309, Cyber Deterrence and Response Act of 2025, all provisions. H.R. 7037, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 7924, Trucking Security and CCP Disclosure Act of 2026, all provisions. H.R. 8516, American Leadership in AI Act, all provisions. H.R. 8558, Defending American Research Act, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9227, Magnets Value Chain Support Act of 2026, all provisions. H.R. 9592, American Space Leadership in the 21st Century Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4525, Securing Innovation and Research from Adversaries Act, all provisions. S. 4565, Strengthening Cyber Resilience Against State-Sponsored Threats Act, all provisions. S. 4570, U.S. Tech Path Act, all provisions. Issues Related to Chinese Biotech Industry and Dual-Use Threats; Chinese Cellular Modules; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Chinese Unmanned Aerial Systems; Chinese, Iranian, and Russian Cyber Operations; Chinese-Made Battery Storage Systems; CISA Resourcing; Cyber-Informed Engineering; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary-Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy; U.S. Cybersecurity Capabilities and Strategy; U.S. Data Security Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Fusion Energy Development; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Nuclear Energy Capabilities; U.S. Quantum Technology Capabilities; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"H.R. 1048, Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act, all provisions. H.R. 8559, No Branch Campuses in Hostile Countries Act, all provisions. H.R. 8901, Securing Innovation and Research from Adversaries Act, all provisions. S. 1296, Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act, all provisions. S. 4423, Defending American Research Act, all provisions. S. 4424, No Branch Campuses in Hostile Countries Act, all provisions. Issues related to Foreign Gift Compliance Transparency; Foreign Influence in Nonprofit Sector; Foreign Influence in U.S. Higher and Elementary Education; and Securing American Funding and Expertise from Adversarial Research Exploitation (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":32,"name":"Education, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"H.R. 6988, Trade Transparency Unit Strategy Act, all provisions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cb76bfb5-8577-4487-a413-a9e8b217d053/","filing_uuid":"cb76bfb5-8577-4487-a413-a9e8b217d053","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/cb76bfb5-8577-4487-a413-a9e8b217d053/print/","filing_document_content_type":"text/html","income":null,"expenses":"1410000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Courtney Piron","dt_posted":"2026-07-20T13:40:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 PENNSYLVANIA AVENUE, NW","registrant_address_2":"Suite 700","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":9204,"url":"https://lda.gov/api/v1/registrants/9204/","house_registrant_id":33589,"name":"NOVARTIS","description":"Federal Government Relations/Legislative Affairs","address_1":"801 Pennsylvania Avenue, NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"COURTNEY PIRON","contact_telephone":"+1 202-662-4364","dt_updated":"2026-07-22T10:55:30.763850-04:00"},"client":{"id":113305,"url":"https://lda.gov/api/v1/clients/113305/","client_id":12,"name":"NOVARTIS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-12-07"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2026 FY 2026 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Federal Budget Funding for National Institutes of Health - FY 2026 Appropriations H.R. 1: One Big Beautiful Bill Act (P.L. 119-21) FY 2027 President's Budget H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program H.R.9504: Tax Exempt Hospital Transparency Act 340B Program Implementation & Oversight H.R. 9599 - SECURE 340B Act Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies Clinical trial data in China S.3788: CLEAR Labels Act S. 4784/H.R. 8800: National Defense Authorization Act for Fiscal Year 2027","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97 H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102 - Biotech Investment National Security Act","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Anti-Trust Reform","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/956076c6-86a3-42ed-bf18-8375d3295b7b/","filing_uuid":"956076c6-86a3-42ed-bf18-8375d3295b7b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/956076c6-86a3-42ed-bf18-8375d3295b7b/print/","filing_document_content_type":"text/html","income":null,"expenses":"7360000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Paul J. Larsen","dt_posted":"2026-07-20T15:46:20-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"670 Maine Avenue, SW","registrant_address_2":"Suite 1000","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":31350,"url":"https://lda.gov/api/v1/registrants/31350/","house_registrant_id":30654,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","description":null,"address_1":"670 Maine Avenue, SW","address_2":"Suite 1000","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL J. LARSEN","contact_telephone":"+1 202-835-3400","dt_updated":"2026-07-30T11:08:37.463508-04:00"},"client":{"id":138226,"url":"https://lda.gov/api/v1/clients/138226/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S.___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.___: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S.___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Presidents Budget Fiscal Year 2027 Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":"None","new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9661: Expedited Access to Biosimilars Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":"None","new":true},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 6089: Biomanufacturing Excellence Act of 2025 H.R. 9102: Biotech Investment National Security Act of 2026 (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":"None","new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e2da4764-9942-4a58-bb71-5df6a3fc754f/","filing_uuid":"e2da4764-9942-4a58-bb71-5df6a3fc754f","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/e2da4764-9942-4a58-bb71-5df6a3fc754f/print/","filing_document_content_type":"text/html","income":null,"expenses":"2440000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jesse Kerns","dt_posted":"2026-07-20T16:02:05-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 13th Street, NW","registrant_address_2":"11th Floor North","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":3867,"url":"https://lda.gov/api/v1/registrants/3867/","house_registrant_id":31560,"name":"AMGEN, INC.","description":null,"address_1":"601 13th Street, NW","address_2":"11th Floor North","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GREG PORTNER","contact_telephone":"+1 202-585-9500","dt_updated":"2026-07-30T12:38:37.840722-04:00"},"client":{"id":103709,"url":"https://lda.gov/api/v1/clients/103709/","client_id":12,"name":"AMGEN INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":14859,"prefix":null,"prefix_display":null,"first_name":"JESSE","nickname":null,"middle_name":null,"last_name":"KERNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18761,"prefix":null,"prefix_display":null,"first_name":"HOWARD","nickname":null,"middle_name":null,"last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":51959,"prefix":null,"prefix_display":null,"first_name":"RUTH","nickname":null,"middle_name":null,"last_name":"HOFFMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144960,"prefix":"ms","prefix_display":"MS.","first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"LOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147106,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCMURRAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147845,"prefix":null,"prefix_display":null,"first_name":"CHAD","nickname":null,"middle_name":null,"last_name":"PETTIT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":14859,"prefix":null,"prefix_display":null,"first_name":"JESSE","nickname":null,"middle_name":null,"last_name":"KERNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18761,"prefix":null,"prefix_display":null,"first_name":"HOWARD","nickname":null,"middle_name":null,"last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":51959,"prefix":null,"prefix_display":null,"first_name":"RUTH","nickname":null,"middle_name":null,"last_name":"HOFFMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144960,"prefix":"ms","prefix_display":"MS.","first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"LOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147106,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCMURRAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147845,"prefix":null,"prefix_display":null,"first_name":"CHAD","nickname":null,"middle_name":null,"last_name":"PETTIT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144960,"prefix":"ms","prefix_display":"MS.","first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"LOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18761,"prefix":null,"prefix_display":null,"first_name":"HOWARD","nickname":null,"middle_name":null,"last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":14859,"prefix":null,"prefix_display":null,"first_name":"JESSE","nickname":null,"middle_name":null,"last_name":"KERNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147106,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCMURRAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/455efc3b-f345-4a6e-8c6c-37b7984e4c83/","filing_uuid":"455efc3b-f345-4a6e-8c6c-37b7984e4c83","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/455efc3b-f345-4a6e-8c6c-37b7984e4c83/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Stacey Scholl","dt_posted":"2026-10-19T09:53:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 Maine Ave. SW Floor 7","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":75557,"url":"https://lda.gov/api/v1/registrants/75557/","house_registrant_id":36051,"name":"CORNERSTONE GOVERNMENT AFFAIRS, INC.","description":"Government relations and consulting.","address_1":"800 Maine Ave. SW Floor 7","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STACEY SCHOLL","contact_telephone":"+1 202-370-1015","dt_updated":"2026-07-15T15:23:57.752080-04:00"},"client":{"id":56037,"url":"https://lda.gov/api/v1/clients/56037/","client_id":56037,"name":"JOHNS HOPKINS UNIVERSITY","general_description":"Healthcare and medical research","client_government_entity":null,"client_self_select":false,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-04-11"},"lobbying_activities":[{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Artificial Intelligence; Research security; S.854/H.R. 1864 - Risky Research Review Act; H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; H.R. 9102, the Biotech Investment National Security Act of 2026","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false},{"lobbyist":{"id":53590,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"SWEAT","suffix":null,"suffix_display":null},"covered_position":"LC, LA & LD House Office (Wicker); LD Sen Member Office (Wicker)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"Establishing a Fixed Time Period of Admission and an Extension of Stay Procedure for Nonimmigrant Academic Students, Exchange Visitors, and Representatives of Foreign Information Media\" final rule (duration of status); H1-B visa fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 9393, the Lower Costs, More Transparency Act of 2026; H.R. 9390, the Prices on the Wall Act of 2026; H.R. 6248/S.4027, the Healthy Competition For Better Care Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Consolidated Appropriations Act, 2027; Office of Management and Budget Regulation for Federal Financial Assistance proposed rule (OMB uniform guidance); FY 2026 and FY 2027 Appropriations research funding; FY 2026 and FY 2027 Labor, Health and Human Services, and Education Appropriations; Advised on High-throughput Materials Discovery For Extreme conditions (HTMDEC) funding","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false},{"lobbyist":{"id":53590,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"SWEAT","suffix":null,"suffix_display":null},"covered_position":"LC, LA & LD House Office (Wicker); LD Sen MemberOffice (Wicker)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Higher education issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false},{"lobbyist":{"id":53590,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"SWEAT","suffix":null,"suffix_display":null},"covered_position":"LC, LA & LD House Office (Wicker); LD Sen MemberOffice (Wicker)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax-exempt status for nonprofit organizations; H.R. 9504, the Tax-exempt Hospital Transparency Act; H.R. 9772, the Foreign Funding Transparency Act; H.R. 9721, the Fiscal Sponsorship Transparency Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/17099c16-1f1a-4b6e-ab8d-d2f5f20ca59b/","filing_uuid":"17099c16-1f1a-4b6e-ab8d-d2f5f20ca59b","filing_type":"3A","filing_type_display":"3rd Quarter - Amendment","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/17099c16-1f1a-4b6e-ab8d-d2f5f20ca59b/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Stacey Scholl","dt_posted":"2026-10-19T12:45:13-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 Maine Ave. SW Floor 7","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":75557,"url":"https://lda.gov/api/v1/registrants/75557/","house_registrant_id":36051,"name":"CORNERSTONE GOVERNMENT AFFAIRS, INC.","description":"Government relations and consulting.","address_1":"800 Maine Ave. SW Floor 7","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STACEY SCHOLL","contact_telephone":"+1 202-370-1015","dt_updated":"2026-07-15T15:23:57.752080-04:00"},"client":{"id":56037,"url":"https://lda.gov/api/v1/clients/56037/","client_id":56037,"name":"JOHNS HOPKINS UNIVERSITY","general_description":"Healthcare and medical research","client_government_entity":null,"client_self_select":false,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-04-11"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Consolidated Appropriations Act, 2027; Office of Management and Budget Regulation for Federal Financial Assistance proposed rule (OMB uniform guidance); FY 2026 and FY 2027 Appropriations research funding; FY 2026 and FY 2027 Labor, Health and Human Services, and Education Appropriations; High-throughput Materials Discovery For Extreme conditions (HTMDEC) funding","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false},{"lobbyist":{"id":53590,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"SWEAT","suffix":null,"suffix_display":null},"covered_position":"LC, LA & LD House Office (Wicker); LD Sen MemberOffice (Wicker)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Higher education issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false},{"lobbyist":{"id":53590,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"SWEAT","suffix":null,"suffix_display":null},"covered_position":"LC, LA & LD House Office (Wicker); LD Sen MemberOffice (Wicker)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax-exempt status for nonprofit organizations; H.R. 9504, the Tax-exempt Hospital Transparency Act; H.R. 9772, the Foreign Funding Transparency Act; H.R. 9721, the Fiscal Sponsorship Transparency Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Artificial Intelligence; Research security; S.854/H.R. 1864 - Risky Research Review Act; H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; H.R. 9102, the Biotech Investment National Security Act of 2026","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false},{"lobbyist":{"id":53590,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"SWEAT","suffix":null,"suffix_display":null},"covered_position":"LC, LA & LD House Office (Wicker); LD Sen Member Office (Wicker)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"Establishing a Fixed Time Period of Admission and an Extension of Stay Procedure for Nonimmigrant Academic Students, Exchange Visitors, and Representatives of Foreign Information Media\" final rule (duration of status); H1-B visa fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 9393, the Lower Costs, More Transparency Act of 2026; H.R. 9390, the Prices on the Wall Act of 2026; H.R. 6248/S.4027, the Healthy Competition For Better Care Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":134466,"prefix":null,"prefix_display":null,"first_name":"CARLOS","nickname":null,"middle_name":"MIQUEL","last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant; House Member Office (Rep. Gwen Moore), Executive Assistant, Special Projects Coordinator, House Member Office (Kleczka)","new":false},{"lobbyist":{"id":56118,"prefix":null,"prefix_display":null,"first_name":"TONY","nickname":null,"middle_name":null,"last_name":"ESSALIH","suffix":null,"suffix_display":null},"covered_position":"COS, LD, LA House Member Office (Culberson), LA House Member Office (Archer), SA House Member Office (Hastings), Intern House Member Office (Bliley)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/8c0099df-681c-43f5-9ba7-c5bc563458d4/","filing_uuid":"8c0099df-681c-43f5-9ba7-c5bc563458d4","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/8c0099df-681c-43f5-9ba7-c5bc563458d4/print/","filing_document_content_type":"text/html","income":null,"expenses":"100000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Christopher Porter","dt_posted":"2026-10-19T20:44:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3611 Valley Centre Drive","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401104190,"url":"https://lda.gov/api/v1/registrants/401104190/","house_registrant_id":null,"name":"TRAVERE THERAPEUTICS","description":"Pharmaceuticals","address_1":"3611 Valley Centre Drive","address_2":"Suite 300","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER PORTER","contact_telephone":"+1 877-969-7879","dt_updated":"2026-07-20T10:56:00.116563-04:00"},"client":{"id":200929,"url":"https://lda.gov/api/v1/clients/200929/","client_id":12,"name":"TRAVERE THERAPEUTICS","general_description":"Biopharmaceuticals","client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/40af1c6b-9956-46d1-811f-51b0cfcd7b8a/","filing_uuid":"40af1c6b-9956-46d1-811f-51b0cfcd7b8a","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/40af1c6b-9956-46d1-811f-51b0cfcd7b8a/print/","filing_document_content_type":"text/html","income":null,"expenses":"440000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-10-19T22:52:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/40af1c6b-9956-46d1-811f-51b0cfcd7b8a/","filing_uuid":"40af1c6b-9956-46d1-811f-51b0cfcd7b8a","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/40af1c6b-9956-46d1-811f-51b0cfcd7b8a/print/","filing_document_content_type":"text/html","income":null,"expenses":"440000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-10-19T22:52:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/51b9daea-c905-4765-80af-535f7f41d935/","filing_uuid":"51b9daea-c905-4765-80af-535f7f41d935","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/51b9daea-c905-4765-80af-535f7f41d935/print/","filing_document_content_type":"text/html","income":null,"expenses":"210000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Bill McCarthy","dt_posted":"2026-10-20T10:45:35-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1800 M Street, NW, Suite 800 S","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":401105458,"url":"https://lda.gov/api/v1/registrants/401105458/","house_registrant_id":null,"name":"FDD ACTION","description":"Issue advocacy on U.S. national security and foreign policy","address_1":"1800 M Street, NW, Suite 800 S","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MCCARTHY","contact_telephone":"+1 202-207-0190","dt_updated":"2026-07-17T14:19:22.246604-04:00"},"client":{"id":203727,"url":"https://lda.gov/api/v1/clients/203727/","client_id":12,"name":"FDD ACTION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-10-01"},"lobbying_activities":[{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"H.R. 1800, Solidify Iran Sanctions Act (SISA), all provisions. H.R. 3447, Chip Security Act, all provisions. H.R. 5334, Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, all provisions. H.R. 5853, ECRA Statute of Limitations Extension, all provisions. H.R. 6275, China AI Power Report Act, all provisions. H.R. 6331, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. H.R. 6875, AI OVERWATCH Act, all provisions. H.R. 7003, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. H.R. 7184, Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, all provisions. H.R. 8005, Stop Pills That Kill Act, all provisions. H.R. 8170, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. H.R. 9450, Countering Russian Trafficking Act, all provisions. H.R. 9721, Fiscal Sponsorship Transparency Act of 2026, all provisions. H.R. 9764, Hindering Oppressive Nations from Obtaining Revenue Act, all provisions. H.R. 9772, Foreign Funding Transparency Act, all provisions. H.R. 9982, Polisario Front Terrorist Designation Act of 2026, all provisions. H.R. 10076, Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, all provisions. S. 1259, Manifest Modernization Act, all provisions. S. 1705, Chip Security Act, all provisions. S. 1889, Solidify Iran Sanctions Act (SISA), all provisions. S. 2904, Sanctioning Harborers And Dodgers Of Western (SHADOW) Sanctions Act of 2026, all provisions. S. 4281, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. S. 4456, AI OVERWATCH Act, all provisions. S. 5025, Lindsey O. Graham Sanctioning Russia Act of 2026, all provisions. S. 5083, Fiscal Sponsorship Transparency Act of 2026, all provisions. S. 5252, Blocking Large-scale Adversarial Distillation Efforts Act of 2026, all provisions. S. 5356, Lebanon Sanctions, Stabilization, and Support Act, all provisions. S. 5379, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. S. 5380, ECRA Statute of Limitations Extension, all provisions. S. 5381, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. S. 5382, China AI Power Report Act, all provisions. S. 5551, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, all provisions. Issues Related to Anti-Money Laundering and Combating the Financing of Terrorism; Captagon, Fentanyl, and International Narcotics Production and Trafficking; Evaluating Sanctions, Export Controls, and AML Regulations, Regulatory Authorities, and Legislative Authorities; Foreign Boycotts of Israel; Foreign Investment in Latin America; Hamas Smuggling Tunnels, Financial Assets, and Funding Streams; IEEPA Reform; Implementation and Oversight of the Countering Americas Adversaries Through Sanctions Act (CAATSA); Iranian Oil Sanctions Enforcement; Monitoring Emerging Economic Security Risks; Muslim Brotherhood Funding Streams; National Security-Related Foreign Investment Screening Processes for U.S. Allies; Non-Western Payment and Messaging Systems; U.S. Adversaries Illicit Finance Activities; U.S. Adversaries Sanctions Evasion Schemes; U.S. China Sanctions Policy; U.S. Corruption Sanctions Policy; U.S. Counter-Kleptocracy Strategy; U.S. Cuba Sanctions Policy; U.S. Digital Assets Policy; U.S. Economic Statecraft Policy; U.S. Export Control Policy; U.S. Hezbollah Sanctions Policy; U.S. Investment Screening and Security; U.S. Iran Sanctions Policy; U.S. Muslim Brotherhood Sanctions Policy; U.S. North Korea Sanctions Policy; U.S. Russia Oil Waivers and Sanctions Policy; U.S. Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; U.S. Terror Finance Policy; and U.S. Turkey Sanctions Policy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"H.R. 3151, SHIPS for America Act of 2025, all provisions. H.R. 4860, U.S.-Taiwan Defense Innovation Partnership Act, all provisions. H.R. 7873 Taiwan Energy Security and Anti-Embargo Act, all provisions. H.R. 8787, Servicemember Payment Data Privacy and Security Act, all provisions. H.R. 9366, Eastern Frontier Defense Infrastructure Readiness Act, all provisions. H.R. 9451, Seized Assets for Battlefield Equipment and Readiness (SABER) Act, all provisions. H.R. 9880, GPS Modernization Acceleration Act, all provisions. H.R.9550, Strategic Unmanned Systems Partnership Act, all provisions. H.R. 10126, Defense Export Modeling Alignment for National Defense (DEMAND) Act, all provisions. H.R. 10766, To direct the Secretary of Defense to update the Critical Asset List of the Department of Defense to incorporate assets critical to the development, deployment, and operation of the Golden Dome missile defense system, all provisions. H.R. 10796, United States-Israel Defense Technology Cooperation Act, all provisions. S. 1541, SHIPS for America Act of 2025, all provisions. S. 2722, Taiwan Energy Security and Anti-Embargo Act, all provisions. S. 4826, Seized Assets for Battlefield Equipment and Readiness (SABER) Act, all provisions. S. 5175, Fast Tracking European Investment in Ukraines Defense Act, all provisions. S. 5548, Securing National Security Systems from Chinese Optical Transceivers Act, all provisions. S. 5590, Electric Grid Supply Chain Security Act, all provisions S. 5595, Weapons Resupply, Stockpile, and Assurance Act, all provisions. S. 5598, Blocking Foreign Cellular Modules in Defense Systems Act of 2026, all provisions. H.R. 8800, National Defense Authorization Act for Fiscal Year 2027, (issues related to Actions to Evaluate and Invest in Ukrainian Defense Technologies; Additional Support for NATO Air Defense Against UAS; AI Agent Discovery and Security Standards; Air Force Fighter Fleet Recapitalization; Amendment to the Atomic Energy Act of 1954; Amendments to the Anti-Boycott Act of 2018; American Security Robotics Act; American-Hellenic-Israeli Eastern Mediterranean Counterterrorism and Maritime Security Partnership Act; Analysis of Threats Posed by Foreign Adversary Access to Controlled Items Within the US; ARMOR Act; Assessment and Report of Foreign Adversary Influence over Strategic Maritime Chokepoints; Assessment of Antisemitism in the Service Academies; Assessment of DOD Display Chain Supply Chain Vulnerabilities; Assessment of Foreign Adversary-Controlled Digital Platforms; Assessment of Military Medical Supply Chains; Assessment of Resilient Missile Defense Sensing Architectures; Assessment of Russian Involvement in Narcotics and Narcotics Trafficking; Audit and Mitigation of Certain Cellular Modules; Audit of CCP-Linked Participation in DOD Contracts and Supply Chains; Baltic Region Security Concerns; Biological Intellectual Property Protection Act; Biotech Investment National Security Act; Briefing on Supply Chain Exposure; Briefing on the Pilot Program to Analyze and Monitor Certain Supply Chains; Bunker Buster Act; Certification Requirement for Motor Carriers Transporting DOD Freight; Certification That No Contractor of DOD Participates in BDS Movement; Chinese Cellular Modules; Chinese Commercial Space Capabilities; Chinese Robotics Capabilities and Strategy; Chinese Supply Chain Monopoly Identification and Diversification; Civilian Cybersecurity Reserve Corps Pilot Program; Clarification of Authority to Counter UAS for Members of the National Guard; Classification of Pass-Through Funding Within Defense Budget Materials; CLEAR Path Act; Codification of EOs Relating to American Airspace Sovereignty and Drone Dominance; Commercial Software for Contested Logistics; Countering Adversarial Gray Zone Campaigns; Countering Biotechnology Threats from Foreign Adversaries; Countering Cartel Hydrocarbon Smuggling; Countering Iranian Threat Networks in the Eastern Mediterranean; Criminal Penalties for Providing Material Support to a Covered Foreign Country; Critical Minerals Traceability Pilot Program; Cyber Incident Reporting Requirements for Operationally Critical Contractors; Deter PRC Aggression Against Taiwan Act; Determination on Eligibility for Cyber Pilot Program; DETERRENCE Act; DETERRENT Act; Development, Test, Evaluation, Demonstration, and Transition to Production of Alternative Low-Cost Weapon Systems; Dialogue and Measures with Respect to Moldova; DIB and Acquisition Reform; Disclosure of Foreign Funding for Elementary and Secondary Schools; DOD Economic Defense Unit; DOD Grant Program to Improve Cybersecurity Resilience of Department-Owned Joint-Use Airports; DOD Procurement Reform; Domestic and Covered Allied or Partner Country Critical Transportation Manufacturing Assessment; Domestic Production of Short-Wave Infrared Quantum Dot Materials; Electromagnetic Spectrum Operations Review; Elimination of Use of Certain Payment Processing Equipment, Systems, or Services; End the Cyprus Embargo Act; Ensuring Mature-node Semiconductor Availability; Establishment of Army Information Operations Center of Excellence; Establishment of China Watcher Program; Establishment of DIU Office in Israel; Establishment of Eastern Flank NATO Regional SOC and CSIRT Program; Establishment of Strategic Airports Cybersecurity Infrastructure Program; Establishment of US-Israel AI Center; Establishment of US-Ukraine Critical Minerals Investment Screening Mechanism; Evaluation of Standards for EMP Protection; Exceptions for Notifications to the US Government Relating to Specified Foreign Entities; Expanding the Defense Industrial Base Sales Act; Expansion of Permissible Uses of Ukraine Support Fund; Extension and Modification of Indo-Pacific Maritime Security Initiative; Extension and Modification of Report on Military and Security Developments Involving the PRC; Extension of Limitation on Availability of Funds for the Iraqi Security Forces; Extension of Report on IRGC-Affiliated Operatives Abroad; FASC Exclusion Orders for Chinese Military Company Designees; Feasibility of Permanent Basing an F-35 Squadron in Poland; Feasibility Study on Combatant Command Critical Minerals Management; Feasibility Study on Tactical Information Operations Command Authority; GAO Report on AI Integration Across Defense Operations; Government-Wide Critical Mineral Procurement and Resale Authorities Feasibility Study; GPS Modernization; GUARD Act; Guard the Skies Act; Hardware and Firmware Assurance Pilot Program; IMF Reform; Increased Maximum Production Capacity Plans for Key Munitions and Weapons Systems; Indo-Pacific Trilateral Production Pilot Program; Integrated Air and Missile Defense Architecture; Integration of Demand for FMS into Industrial Base Planning; Internal Base Hardening Assessments and Logistics-Node Threat Mitigation; Joint DOD-DHS Security Pilot Program on Prevention of Terrorist Threats Involving Motor Vehicles; Joint US-Taiwan Research, Development, Test, and Evaluation Program; Limitation on Provision of Funds to Elementary and Secondary Schools Hosting Confucius Institutes and Classrooms; Long Range Anti-Ship Missile Surface and Ground Launch; Maritime Security Measures; Medical Supply Chain Risk Identification and Transparency Enhancement; Military Treatment Facility Readiness, Network Reliance, and Cyber Resilience; Modification of Report on Military and Security Developments Involving Russia; Modification of Report on the Military Power of Iran; Modification to Disclosure Requirements for US-Based Foreign Media Outlets; Modifications to Congressional Review of Sanctions with Respect to Russia; Modifications to Public Reporting of Chinese Military Companies Operating in the US; Modifications to Strategy to Eliminate Sourcing of Computer Displays from Certain Nations; Modifications to the Port Security Grant Program; Moldovas Airspace Awareness and Defense Capabilities; MTS Cyber Act; Multiyear Procurement Authorities; National Security Commission on Robotics; NSA Support for DIB and Critical Infrastructure Cybersecurity Operations; Oversight of Military-to-Military Exchanges and Contacts Between the US and Russia; PAID OFF Act; Participation of Ukrainian Students in US Service Academies; Phased Inventory Benchmarks for Combat Coded Fighter Aircraft; Photovoltaic Modules from Foreign Entities of Concern; PILLAR Act; Pilot Program for Adaptive Electronic Warfare-Resilient and Quantum-Secure Autonomy Small UAS Architecture Testing; Pilot Program on DOD Partnerships with IHE Recognized in the NCAE-C Program for Cyber Research; Pilot Program on National Security Risk Identification and Review for Adversarial Capital; Pilot Program on Semiconductor Antitampering and Authenticity Validation; Pilot Program to Improve Participation by Small Business Concerns in Certain DOD Contracts; Plan on Remediation of Certain Equipment and Computational Facilities Owned or Controlled by a Foreign Adversary; Plan Required for Full Participation by Taiwan in the RIMPAC; Plan to Counter PRC Influence and Activities in the FAS; Potential Designation of Information as a Domain of Warfare; PRC Militarization and Surveillance Activities; Procurement of Amoxicillin; Prohibition Against US Recognition of Russia's Claim of Sovereignty over Any Portion of Ukraine; Prohibition on DOD Procurement from, and Servicemember Data Collection by, Companies Storing Data in a Covered Foreign Country; Prohibition on Operation or Procurement of Foreign-Made UAS; Prohibition on Procurement and Operation of Covered Robotic Systems; Prohibition on Procurement by DOD and IC of Chinese-Made Synthetic Datasets for Training AI Models; Prohibition on Transfers to the Badr Organization; Prohibition on TSP Investments; Prohibition on Use of Funds for Ukraine Security Assistance; Protecting US Farmland and Sensitive Sites from Foreign Adversaries Act; Protection of Supply Chain of Certain Drugs; Rail Infrastructure Cybersecurity Enhancement Program; Real-Time and AI-Enabled Property Records; Report and Conditions on Security Assistance to Oman; Report on Accelerating Military Posture Within Area of Responsibility of US INDOPACOM; Report on Counterintelligence Risks Associated with Real Property Transactions Near Military Installations; Report on Dependency on China for Processing Materials for DOD Supply Chains; Report on Forced Conscription of Kidnapped Ukrainian Children into Russian Armed Forces; Report on Foreign-Linked Funding of Legal and Administrative Actions Targeting US and Allied Personnel; Report on Global Automobile Theft Rings; Report on Instances of Antisemitism; Report on Involvement of Certain Foreign Actors in Antisemitic Activity in the US; Report on Military Power and Illicit Activities of Certain Drug Cartels; Report on Modernization of the Aegis Ashore Missile Defense Site at Devesselu, Romania; Report on Moldova Airspace Defense Requirements and Options; Report on PRC Space Capabilities; Report on Production of 155MM Artillery Ammunition; Report on Protection of US Defense Technology; Report on Russias Targeting of Religious Infrastructure in Ukraine; Report on Russian Active Measures in NATO Territory; Report on Russian Efforts in Sudan; Report on Russian Influence in Libya; Report on Russian Influence; Report on Russian Military Presence in Syria; Report on Security Risks Posed by Turkeys Occupation of Cyprus; Report on Taiwan Capabilities and Intelligence Support; Report on the Feasibility of Requiring Bills of Materials for Defense Acquisition; Report on the National Security Implications of Applying Nondiscriminatory Treatment to the PRC; Report on the PRC and Turkey Military and Intelligence Cooperation; Report on Turkey Aiding Hamas or Its Affiliates; Report to Congress on Energy in Moldova; Reporting on Russias Military Power and Capabilities; Reports on Cyber Operational Readiness Assessment Program; Re-Purposing Aircraft from the 309th AMARG; Requirement for Guidance and Prohibition on Use of AI of Certain AI Companies; Requirement for Memoranda of Agreement Regarding Vulnerability Disclosure and Prohibition on Procurement from IT Providers Who Can Share Cyber Vulnerabilities with Countries of Concern; Requirements Related to Certain Sanctions on Russia or Belarus; Restriction on Providing Federal Funds to Certain Entities for Public Works Projects; Restrictions on US Support for Economic Activities Involving Persons Who Benefitted from or Supported the Assad Regime; Review of Intelligence Vulnerabilities of Internet Connected Video Surveillance Equipment on Military Installations; Revocation of Security Clearances for Certain Persons; Safeguarding DOD-Funded Research; Securing Critical US Infrastructure and Mineral Supply Chains; Securing DOD Supply Chains; Securing Innovation and Research from Adversaries Act; Seizure and Forfeiture of Assets of Russian Kleptocrats; Semiconductor Controls Adjusted to Limit Exports Act; Semiconductor Supply Chain Security and Diversification Act; Sense of Congress on Commitment to the AUKUS Partnership; Sense of Congress on Domestic Production of Artillery Projectiles; Sense of Congress on International Defense Exhibitions; Sense of Congress on Nuclear Cooperation Agreements with Saudi Arabia; Sense of Congress on the Gaza Health Ministry; Sense of Congress on the Permanent and Rotational Presence of US Forces in Romania; Sense of Congress Regarding Kosovo Integration into NATO; Sense of Congress Regarding NATO's Kosovo Force; Sense of Congress with Respect to Execution of Warrants of the ICC; Space-Based Missile Defense Strategy; Standards for AI Systems; Strategic Partnership on Defense Industrial Priorities Between the US and Taiwan; Strategy for Establishing a Two-Way Transfer Mechanism for US-Ukraine UAS Expertise; Strategy for the Adoption and Integration of AI; Strategy to Defend Against Risks Posed by the Use of AI; Strategy to Restore Stability to the Western Balkans; Strengthening Continuity of the Economy Planning; Study and Report on International Security Measures on the Border Between Gaza and Egypt; Study, Strategy, and Report on DOD Reliance on Transportation Systems Incorporating Chinese-Origin Components; Taiwan-Five Eyes Cyber Defense Cooperation Initiative; Training for Ukraines Military and National Security Forces; Transatlantic Growth Enterprise Act; Tren de Aragua Border Security Threat Assessment Act; Ukraine Drone Production and Strategy; Ukrainian Military Instructors at Senior Professional Military Education Institutions; Updated Middle East IAMD Strategy; Updates to Certain Asset Lists of the DOD; Upholding the Dayton Peace Agreement Through Sanctions Act; US Counter-Robotics Strategy; US Cybersecurity Capabilities and Strategy; US Drone and Missile Defense Capabilities; US Force Posture in Korea and Europe, US Information Operations Capabilities and Strategy; US International Legal Operations Strategy; US Military Posture in Europe; US-Abraham Accords Defense Cooperation Initiative; US-Cyprus Security Cooperation; USDT Report on Financial Institutions That Support Terrorist Activity; US-European Nuclear Energy Cooperation Act; US-Greece Security Cooperation Reporting Act; US-Israel Cooperation on Space Matters; US-Israel Cooperative Research and Development; US-Israel Defense Technology Cooperation Initiative; US-Israel Security Cooperation; US-Taiwan Security Cooperation; US-Ukraine Drone Working Groups; US-Ukraine EOD Partnership; US-Ukraine Military Trauma Education, Training, Research, and Medical Readiness Partnership; and US-Ukraine Security Cooperation). S. 4784, National Defense Authorization Act for Fiscal Year 2027, (issues related to Abraham Accords Defense Cooperation Initiative; AI Functional Bill of Materials; Analysis of Threats Posed by Foreign Adversary Access to Controlled Items Within the US; Assessment of Taiwans LNG Supply Chains; Assistance to LAF for Countering Hezbollah and Other Terrorist Groups; Audit and Mitigation of Covered Cellular Modules in the DOD Systems and Infrastructure; Briefing on Military and Intelligence Presence of Cuba in the Western Hemisphere; Chinese Cellular Modules; Codification of DOD Research Security Program; Countering Cartel Hydrocarbon Smuggling; Cybersecurity Training for Veterans and Military Spouses; Derived Sourcing Requirements for AI Outputs; DETERRENCE Act; DETERRENT Act; DLA Warstopper Program; DOD Economic Defense Unit; Expansion of Permissible Uses of Ukraine Support Fund; Extension and Modification of Pacific Deterrence Initiative; Extension of Report on Military Power of the PRC; Extension, Modification, and Redesignation of Taiwan Security Cooperation Initiative; Full Accountability for Chinese Military Companies; Inspector General for Foreign Assistance; Internal Base Hardening and Staged Internal Operations; Middle East IAMD Architecture; Modifications to Requirement for Public Reporting of Chinese Military Companies Operating in the US; Multiyear Procurement Authorities; PAID OFF Act; Plan on Remediation of Certain Equipment and Computational Facilities Owned or Controlled by a Foreign Adversary; PRC EMP Capabilities; Report on the Feasibility and Advisability of Establishing a Strategic Partnership on Defense Industrial Priorities between the US and Israel; Reports on Foreign Boycotts of Israel; REVOKE Act; Safeguarding DOD-Funded Research; SECURE Minerals Act; Securing Critical Weapons Systems Supply Chains; Securing US Military Mobility Infrastructure; Securing US Transportation Systems; Stop Foreign Spyware Act; Strategic Subsea Cables Act; Taiwan Energy Security and Embargo Act; Ukraine Drone Production and Strategy; US AI Policy; US Airport Cybersecurity Enhancements; US Critical Infrastructure Resilience Against EMP Weapons; US Cybersecurity Capabilities and Strategy; US Drone and Missile Defense Capabilities; US Healthcare Cybersecurity Enhancements; US Highways Cybersecurity Enhancements; US Indo-Pacific Policy and Strategy; US Maritime Cybersecurity Enhancements; US Rail Infrastructure Cybersecurity Enhancements; US Space Capabilities and Strategy; US-India Security Cooperation; US-Israel Defense Technology Cooperation Initiative; US-Israel Security Cooperation; US-Taiwan Security Cooperation; US-Ukraine Security Cooperation; and US-Ukraine Strategic Defense Innovation Working Group). Issues Related to AUKUS Support; China-Iran-DPRK-Russia Security Cooperation and Technology Development; Chinas Military-Industrial Complex (CMIC); Chinese Military Companies; Defending Freedom of Navigation; Defense Industrial Base Modernization and Reform; DOD Diffusion of Artificial Intelligence; DODs Economic Defense Unit; Domestic and Allied Nuclear Energy Supply Chains; Domestic Production of Short-Wave Infrared Quantum Dot Materials; Hardening U.S. Military Assets and Bases; Implementation and Oversight of the NDAA (FY24 - FY26); Irans Military Strategy and Capabilities; Irans Network of Terror Proxies; Iranian Weapons Proliferation; Middle East Integrated Air and Missile Defense Architecture; Middle East Water and Food Security Working Group; Military Capability and Capacity of U.S. Allies; North Koreas Military Strategy and Capabilities; PRC Militarization and Surveillance Activities; Rebuilding U.S. Munitions Stockpile; Securing U.S. Supply Chains for Critical Weapons Systems and Munitions; U.S. Arms Control Policy; U.S. Counter-Cartel Strategy; U.S. Drone and Missile Defense Capabilities; U.S. Information Operations Capabilities and Strategy; U.S. International Legal Operations Strategy; U.S. Military Funding and Equipment; U.S. Military Operational Security Requirements; U.S. Military Posture in Europe; U.S. Military Posture in the Indo-Pacific; U.S. Military Posture in the Middle East; U.S. Nuclear Deterrence Strategy; U.S. Operations In and Against Iran; U.S. Policy on Irans Ballistic Missile and Nuclear Programs; U.S. Policy on Irans Support for Terrorism; U.S. Policy on Russias War in Ukraine; U.S.-Iraq Security Cooperation; U.S.-Israel Security Cooperation; U.S.-Lebanon Security Cooperation; U.S.-NATO Security Cooperation; U.S.-ROK Security Cooperation; U.S.-Saudi Arabia Security Cooperation; U.S.-Taiwan Security Cooperation; U.S.-Turkey Security Cooperation; U.S.-Ukraine Security Cooperation; and War Reserve Stockpiles for Allies (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"H. Res. 1618, Recognizing the third anniversary of the October 7, 2023, terrorist attacks on Israel, honoring the victims and the hostages, and calling for the complete disarmament of Hamas for a durable end to the war in Gaza, all provisions. H.J. Res. 200, Providing for congressional disapproval of the proposed foreign military sale to Turkey of certain defense articles and services, all provisions. H.R. 36, MEGOBARI Act, all provisions. H.R. 3307, Eastern Mediterranean Gateway Act, all provisions. H.R. 4215, International Traffic in Arms Regulations Licensing Reform Act, all provisions. H.R. 6469, Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act, all provisions. H.R. 7380, IRAN Act, all provisions. H.R. 7622, Iran Human Rights, Internet Freedom, and Accountability Act of 2026, all provisions. H.R. 9039, Preserving Accountability for National Assets Act of 2026, all provisions. H.R. 9147, Abraham Accords Expansion Act of 2026, all provisions. H.R. 9680, Replace UNRWA with Real Humanitarian Assistance Act, all provisions. H.R. 10008, Turkey Human Rights Promotion Act of 2026, all provisions. H.R. 10183, Supporting the Rule of law, Building Institutional Justice, and Accountability (SRBIJA) Act, all provisions. H.R. 10473, Justice for Ukrainian Children Act, all provisions. H.R. 10757, To provide for a limitation on contributions to the United Nations, all provisions. S. 3360, Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act, all provisions. S. 3900, Iran Human Rights, Internet Freedom, and Accountability Act of 2026, all provisions. S. 4379, Russias War on Faith Act, all provisions. S. 4443, Eastern Mediterranean Gateway Act, all provisions. S. 4723, Eliminate PRC Organized Crime Act, all provisions. S. 5205, Turkey Human Rights Promotion Act of 2026, all provisions. S. 5611, Supporting the Rule of law, Building Institutional Justice, and Accountability (SRBIJA) Act, all provisions. H.R. 8800, National Defense Authorization Act for Fiscal Year 2027, (issues related to Abraham Accords Central Asia Expansion Act; Abraham Accords Authorities Expansion; Accountability for Terrorist Perpetrators of October 7th Act; Arms Delivery Queue Report; Arms Sales and Weapons System Transfers to NATO countries; Authorization of Activities to Counter Russia; BANNED in Latin America Act; Business in the Balkans; Captagon, Fentanyl, and International Narcotics Production and Trafficking; Certification Requirement for Major Arms Sales to Turkey; Closing Loopholes in Russia Sanctions; Countering Russias War on Faith Act; Deployment of a Financial Attache to the US Embassy in Jerusalem; Deterring Adversary Ill-Gotten Gains Act; AI OVERWATCH Act; American Space Leadership for the 21st Century Act; BIS License Administration Enhancement Act; BIS STRENGTH Act; Block the Use of Transatlantic Technology in Iranian Made Drones Act; China AI Power Report Act; Chip Security Act; Countering Chinas Control of the Caucasus; Countering Russias Forced Recruitment and Kidnapping in Africa Act; Deterring American AI Model Theft Act; Dismantle Foreign Scam Syndicates Act; Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act; Decreasing Russia Oil Profits (DROP) Act; ECRA Penalty Increase Act; ECRA Statute of Limitations Extension; Enhanced Iran Sanctions Act; Export Control Enforcement and Enhancement Act; Export Controls Enforcement Act; Foreign Adversary AI Risk Assessment and Diplomacy Act; Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act; Full AI Stack Export Promotion Act; Interagency Coordination in Export Controls Act; Interagency Strategy to Disrupt and Dismantle Narcotics Production and Trafficking and Affiliated Networks Linked to the Regime of Bashar al-Assad in Syria; ITAR Licensing Reform Act; Kleptocracy Asset Recovery Rewards Program Act; Limitation on Contributions to the UN; Limitation on Transfer of Weapons to Turkey; Limitation Regarding Certain Export Controls; Multilateral Alignment of Technology Controls on Hardware (MATCH) Act; MEGOBARI Act; No US Funding for UNIFIL Act; No Official Palestine Entry (NOPE) Act; Participation of Russia in the G7; Preventing the Escalation of Armed Conflict in Europe (PEACE) Act; Peace Through Strength Act; Polisario Front Terrorist Designation Act; Preventing Rogue Equipment for Synthetic Substances (PRESS) Act; Prohibition on Delay of Arms Sales to Taiwan; Remote Access Security Act; REPO Implementation Act; Report on Allied Information Sharing to Counter Foreign Malign Influence; Report on Backlog of FMS to Taiwan; Russia-North Korea Cooperation Sanctions Act; Sanctions List Harmonization Act; Strategic Hybrid Activities Defense and Operations for the West (SHADOW) Act; STOP HATE Act; Stop Stealing Our Chips Act; Strategic Dialogue to Return Democratic Rule to Belarus; Strategic Subsea Cables Act; Streamlining Foreign Military Sales Act; Semiconductor Technology Resilience, Integrity, and Defense Enhancement (STRIDE) Act; Taiwan Allies Fund Act; Taiwan Energy Security and Anti-Embargo Act; Taiwan PLUS Act; US Arms Sales and Procurement Strategies; US Iran Sanctions Policy; US Support for the Iranian People; War Reserve Stockpiles for Allies; and XPCC Sanctions Act). S. 4784, National Defense Authorization Act for Fiscal Year 2027, (issues related to BANNED in Latin America Act; BIS License Administration Enhancement Act; BIS STRENGTH Act; China AI Power Report Act; Chip Security Act; Countering Chinas Control of the Caucuses Act; Critical Undersea Infrastructure Resilience Initiative Act; Deterring American AI Model Theft Act; Eastern Mediterranean Gateway Act; ECRA Statute of Limitations Extension Act; Eliminate PRC Organized Crime Act; FREEDOM Act; Imposition of Sanctions with Respect to Trade in Russian Origin Petroleum Products; Iran Human Rights, Internet Freedom, and Accountability Act; MATCH Act; MEGOBARI Act; No Hezbollah In Our Hemisphere Act; PORCUPINE Act; Religious Infrastructure in Ukraine; Remote Access Security Act; REPO Implementation Act; Sense of Congress on Illegal Abduction of Ukrainian Children by Russia; SHADOW Fleet Sanctions Act; Statement of Policy on Repeal of Sunset of Iran Sanctions Act of 1996; US Iran Sanctions Policy; US Legal Gold and Mining Partnership Act; US Russia Oil Waivers and Sanctions Policy; US Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; US South Africa Bilateral Relations Review Act; and War Reserve Stockpiles for Allies). Issues related to China-Turkey Relations; Chinas Foreign Policy and Military Strategy; Chinese Activities in Latin America; Chinese Proliferation of Dual-Use Technology; Compensation for U.S. Victims of Iranian Terrorism; Congressional Oversight of U.S. Arms Sales; Congressional Oversight of U.S. Foreign Assistance; Democracy Programs in Latin America; Foreign Influence in Media; Implementation and Oversight of the Iran Nuclear Agreement Review Act; Implementation of the Atomic Energy Act; Implementation of the National Security Act of 2024; India-Middle East-Europe Economic Corridor (IMEC); Israel-Lebanon Framework Agreement; Middle East Peace Plan Implementation and Oversight; Near East Regional Democracy Program Funding; Normalization in the Middle East; Protecting International Religious Freedom; Russias Mass Abduction of Ukrainian Children; Sportswashing by U.S. Adversaries; Support for U.S. Allies at International Organizations; Turkeys Support of Terrorism; U.S. Arms Sales and Procurement Strategies; U.S. Bosnia Policy and Relations; U.S. Contributions to and Oversight of International Organizations; U.S. Energy Security Policy; U.S. Foreign Aid Policy and Reform; U.S. Global Health Policy; U.S. Policy on Chinas Human Rights Abuses and Repression; U.S. Policy on Irans Human Rights Abuses and Censorship; U.S. Policy on North Koreas Human Rights Abuses and Censorship; U.S. Serbia Policy and Relations; U.S. Support for the Iranian People; U.S. Western Balkans Strategy; U.S.-Albania Policy and Relations; U.S.-Cuba Policy and Relations; U.S.-Iran MOU and Negotiations; U.S.-Iraq Policy and Relations; U.S.-Latin America Foreign Policy and Strategy; U.S.-Mexico Policy and Relations; U.S.-Moldova Policy and Relations; U.S.-Nicaragua Policy and Relations; U.S.-Saudi 123 Agreement; U.S.-South Africa Policy and Relations; U.S.-Turkey Policy and Relations; and U.S.-Venezuela Policy and Relations (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"H.R. 6105, Restricting Ex-Vetted Officials from Knowledge Exploitation (REVOKE) Act, all provisions. H.R. 6106, Conflict-free Leaving Employment and Activity Restrictions (CLEAR) Path Act, all provisions. H.R. 6107, Preventing Adversary Influence, Disinformation, and Obscured Foreign Financing (PAID OFF) Act of 2025, all provisions. H.R. 8168, Major Non-NATO Ally Terror Threat Assessment Act, all provisions. H.R. 9492, Cybersecurity Logging Enforcement and Accountability Reporting Act, all provisions. H.R. 9834, No Racketeers on our Shores Act, all provisions. S. 2132, CLEAR Path Act, all provisions. S. 3050, Preventing Adversary Influence, Disinformation, and Obscured Foreign Financing (PAID OFF) Act of 2025, all provisions. S. 3181, REVOKE Act, all provisions. S. 4697, Stop TNR Act of 2026, all provisions. S. 4699, Guaranteeing Universal Access to Cybersecurity Act, all provisions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"H.R. 2683, Remote Access Security Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 8283, Deterring American AI Model Theft Act of 2026, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9592, American Space Leadership for the 21st Century Act, all provisions. H.R. 10670, China FIREWALL Act, all provisions. H.R. 10695, United States Submarine Cable Security Policy Act of 2026, all provisions. S. 3519, Remote Access Security Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4939, Countering CCP Act, all provisions. S. 5316, Biotech Investment National Security Act (BINSA), all provisions. Issues Related to Adversarial Distillation of American AI Models; Chinese Biotech Industry and Dual-Use Threats; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; National Security Capabilities of Advanced AI Systems; NATO Cybersecurity Capabilities and Strategy; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; TikTok Operations and Safeguards; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy and Regulation; U.S. Cybersecurity Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Open Technology Fund; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy; and U.S. Technology-Security Strategy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"H.R. 1048, Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act, all provisions. H.R. 8901, Securing Innovation and Research from Adversaries Act, all provisions. H.R.1049, Transparency in Reporting of Adversarial Contributions to Education (TRACE) Act, all provisions. S. 1296, Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act, all provisions. S. 2509, Transparency in Reporting of Adversarial Contributions to Education (TRACE) Act, all provisions. Issues related to Foreign Gift Compliance Transparency; Foreign Influence and Investments in Nonprofit Sector; Foreign Influence and Investments in U.S. Higher and Elementary Education; and Securing American Funding and Expertise from Adversarial Research Exploitation (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to Illegal Transshipment of Goods (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"INT","general_issue_code_display":"Intelligence","description":"Issues related to Foreign Malign Influence Operations (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e1e81663-8dc7-4a88-bedb-b1e005aba204/","filing_uuid":"e1e81663-8dc7-4a88-bedb-b1e005aba204","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/e1e81663-8dc7-4a88-bedb-b1e005aba204/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Stephen P. Roberts, Attorney & Agent for Filer","dt_posted":"2026-10-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 Main Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Cambridge","registrant_state":"MA","registrant_zip":"02139","registrant":{"id":401103747,"url":"https://lda.gov/api/v1/registrants/401103747/","house_registrant_id":null,"name":"SACHEM STRATEGIES","description":"Lobbying firm","address_1":"750 Main Street","address_2":null,"address_3":null,"address_4":null,"city":"Cambridge","state":"MA","state_display":"Massachusetts","zip":"02139","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NATHANIEL WALTON","contact_telephone":"+1 617-780-2252","dt_updated":"2026-07-30T17:42:40.417693-04:00"},"client":{"id":69985,"url":"https://lda.gov/api/v1/clients/69985/","client_id":69985,"name":"STRAND THERAPEUTICS","general_description":"mRNA therapeutics company","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-10-06"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to biomanufacturing policy (H.R. 9102 / S. 5316 Biotech Investment National Security Act).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62270,"prefix":null,"prefix_display":null,"first_name":"NATHANIEL","nickname":null,"middle_name":null,"last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cb8d32e9-83d7-48be-b71a-d96e2736dd8d/","filing_uuid":"cb8d32e9-83d7-48be-b71a-d96e2736dd8d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/cb8d32e9-83d7-48be-b71a-d96e2736dd8d/print/","filing_document_content_type":"text/html","income":null,"expenses":"3600000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Skelton","dt_posted":"2026-10-20T14:54:17-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1275 Pennsylvania Avenue, NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":31326,"url":"https://lda.gov/api/v1/registrants/31326/","house_registrant_id":31354,"name":"PFIZER INC.","description":"Biopharmaceuticals","address_1":"1275 Pennsylvania Avenue, NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-08-21T13:00:31.079287-04:00"},"client":{"id":138225,"url":"https://lda.gov/api/v1/clients/138225/","client_id":12,"name":"PFIZER INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72512,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"CLAEYS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69774,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/57575736-484a-471b-916b-2b2bf41eb4fe/","filing_uuid":"57575736-484a-471b-916b-2b2bf41eb4fe","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/57575736-484a-471b-916b-2b2bf41eb4fe/print/","filing_document_content_type":"text/html","income":null,"expenses":"3150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jesse Kerns","dt_posted":"2026-10-20T16:03:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 13th Street, NW","registrant_address_2":"11th Floor North","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":3867,"url":"https://lda.gov/api/v1/registrants/3867/","house_registrant_id":31560,"name":"AMGEN, INC.","description":null,"address_1":"601 13th Street, NW","address_2":"11th Floor North","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GREG PORTNER","contact_telephone":"+1 202-585-9500","dt_updated":"2026-07-30T12:38:37.840722-04:00"},"client":{"id":103709,"url":"https://lda.gov/api/v1/clients/103709/","client_id":12,"name":"AMGEN INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":14859,"prefix":null,"prefix_display":null,"first_name":"JESSE","nickname":null,"middle_name":null,"last_name":"KERNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18761,"prefix":null,"prefix_display":null,"first_name":"HOWARD","nickname":null,"middle_name":null,"last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":51959,"prefix":null,"prefix_display":null,"first_name":"RUTH","nickname":null,"middle_name":null,"last_name":"HOFFMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144960,"prefix":"ms","prefix_display":"MS.","first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"LOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147106,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCMURRAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147845,"prefix":null,"prefix_display":null,"first_name":"CHAD","nickname":null,"middle_name":null,"last_name":"PETTIT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147106,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCMURRAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147845,"prefix":null,"prefix_display":null,"first_name":"CHAD","nickname":null,"middle_name":null,"last_name":"PETTIT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":14859,"prefix":null,"prefix_display":null,"first_name":"JESSE","nickname":null,"middle_name":null,"last_name":"KERNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18761,"prefix":null,"prefix_display":null,"first_name":"HOWARD","nickname":null,"middle_name":null,"last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":51959,"prefix":null,"prefix_display":null,"first_name":"RUTH","nickname":null,"middle_name":null,"last_name":"HOFFMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144960,"prefix":"ms","prefix_display":"MS.","first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"LOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":33334,"prefix":null,"prefix_display":null,"first_name":"L","nickname":null,"middle_name":"NICOLE","last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":33612,"prefix":null,"prefix_display":null,"first_name":"WILLIAM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36188,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"RHEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144960,"prefix":"ms","prefix_display":"MS.","first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"LOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138086,"prefix":"mrs","prefix_display":"MRS.","first_name":"JORDAN","nickname":null,"middle_name":"LYNN","last_name":"LAYSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18761,"prefix":null,"prefix_display":null,"first_name":"HOWARD","nickname":null,"middle_name":null,"last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":14859,"prefix":null,"prefix_display":null,"first_name":"JESSE","nickname":null,"middle_name":null,"last_name":"KERNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147106,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCMURRAY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147846,"prefix":null,"prefix_display":null,"first_name":"CHASE","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":13124,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"PORTNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7b7372e1-551f-4eac-afa5-105a6670c2fe/","filing_uuid":"7b7372e1-551f-4eac-afa5-105a6670c2fe","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/7b7372e1-551f-4eac-afa5-105a6670c2fe/print/","filing_document_content_type":"text/html","income":null,"expenses":"1530000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-10-20T16:45:00-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #1000","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}